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Clinical study on diabetic nephropathy. C-H. Park, C- Y. Ha, S-K.
Park, and S-K. Kang, Department of Internal Medicine, Chonbuk
National University, Medical School, Chonju, Chonbuk, Korea. In
1971, Dr. Marks reported that the percent of deaths caused by diabetic
nephropathy in Korea was 8.9%. Since the number of diabetic patients
is rising in Korea, a study on diabetic nephropathy was done. Of the
11,619 patients admitted to Chonbuk National University Hospital,
Department of Internal Medicine from 1986 to December 1990, diabetes
was diagnosed in 722 (6.2%) patients. Of the 247 possible candidates,
authors have done follow-up study on 98 patients (39.7%) who showed
signs of diabetic nephropathy with (+) proteinuria and serum creatinine
of over 1.5 mg/dl. Fifty to 60 years of age was most common, with a
mean of 61.3 years, and the male-to-female ratio was 1.6:1. Duration
since diabetic diagnosis was 32.7% for 6-10 years and 5.1% for 21—25
years. Onset of diabetes before age 29 was in 16 cases, and onset during
ages 30—39 was found in 24 cases, thus showing that onset before age of
40 was found in 40.8%. Of these patients, 2 had renal transplantation, 12
cases are currently on CAPD and 5 patients on dialysis. Diagnosis of
diabetes after age of 40 was made in 58 (59.2%) patients. Of these
patients, 2 cases had renal transplantation, 8 cases are currently on
CAPD and 8 cases on dialysis. Of the total diabetic nephropathy
patients 13.3% died of unknown cause.
Clinical featw'es of diabetic patients with end-stage renal disease who
are on hensodialysis. S.K. Rhee, M.S. Jeong, S.H. Shin, G.W. Yi, Y.T.
Shin, and Y.K. Kim, Department of Internal Medicine, College of
Medicine, Chungnam National University, Daejeon, Korea, Glomeru-
lonephritis, in its several forms, was the most common initiating cause
of chronic renal failure in the past. In recent years, diabetes mellitus has
become the leading cause of end-stage renal disease in Korea. The
clinical features of 30 cases of diabetic patients among 265 patients,
from January 1985 to December 1990, who began hemodialysis treat-
ment in Chungnam National University Hospital, were reviewed retro-
spectively. (1) The rate of diabetic ESRD was 11.4% (30 of 265 new
ESRD) during the past 6 years, but the annual rate diabetic ESRD
increased year by year. In 1990, diabetic ESRD was attributed to 33.3%
of the new ESRD patients. (2) In diabetic patients, hemodialysis was
started about 13.3 years after diagnosis of diabetes. The average age of
patients on dialysis was 40.6 (± 3.67) years in the control group and 55.7
(± 10.94) years in diabetic patients, which is significantly different (P <
0.001). The sex distribution was not significantly different. (3) Fluid
overload was the most common initiating cause of dialysis in both
groups and the order of frequency was symptomatic uremia, resistant
hyperkalemia, pericarditis and severe acidemia, (4) Serum creatinine
levels checked just before hemodialysis were 14.1 (± 6.38) mgldl in the
control group and 8.7 (± 4.82) mgldl in diabetic patients, which was
significantly different (F <0.001). Thirty percent of the diabetic patients
started hemodialysis on serum creatinine concentration below 5 mg/dl,
but only 5.6% of the control group did. The initiating causes of
hemodialysis in diabetic patients whose serum creatinine level was
below 5.0 mg/dl were uremic symptoms (44.4%), fluid overload (44.4%)
and resistant hyperkalemia (11.2%). (5) The serum phosphorus levels
checked just before hemodialysis were 7.4 (± 2.46) mg/dl in control
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group and 5.5 (± 1.80) mgldl in diabetic patients, which was signifi-
cantly different (P < 0.001). (6) The serum calcium, potassium, albumin
and hemoglobin levels checked just before hemodialysis were not
statistically different between the two groups.
Clinical characteristics of regularly hemodialyzed patients with diabe-
tes meltitus. Y.S. Kim, S.A. Yoon, S.f. Ahn, J. Y. Woo, I.S. Park, S. Y.
Kim, W.S. Koo, Y.S. Chang, Y.S. Yoon, and B.K. Bang, Department
of Internal Medicine, Catholic University Medical College, Seoul,
Korea. Dialysis experience in our five centers is summarized; diabetic
patients received hemodialysis regularly for more than 3 months, with
respect to their actuarial survival and complication. To more clearly
elucidate the magnitude of the problem, some of the results achieved in
diabetic patients were compared to our experience in treating two
groups of nondiabetic patients: those over 50 years of age and those
under 50. In 60 diabetic patients, 273 nondiabetic patients under 50 and
128 nondiabetic patients over 50, M:F ratios were 2:1, 1.5:1, 1.3:1,
respectively, mean ages when dialysis started were 55 years, 35 years,
and 57 years, and median periods of hemodialysis were 18 months, 24
months, and 27 months, respectively. In diabetic patients the mean age
at onset of diabetes was 38 years and median duration of diabetes was
19 years. Currently among 60 diabetic patients: 33 patients died, 2
patients withdrew from the program alive (1 patient transferred to
peritoneal dialysis and 1 patient received renal allograft) and 25 patients
continued hemodialysis. In diabetic, nondiabetic under 50, and nondi-
abetic over 50 patients, the actuarial patient survival rates at 1 year
were 79%, 94%, 85%, respectively; those at 2 years were 59%, 82%,
71%, and those at 5 years were 21%, 66%, 51%, respectively. Cardiac
disease and cerebrovascular accident were the leading causes of death
in both diabetic and nondiabetic patients. Diabetic patients had more
complications during dialysis. The complications were hypertension,
diabetic retinopathy, cerebrovascular accident, isehemic heart disease,
pulmonary edema in diabetic patients and were hypertension, ischemic
heart disease, pulmonary edema, arrhythmia, cerebrovascular accident
in nondiabetic patients in the order named. In conclusion, hemodia-
lyzed patients with diabetes mellitus showed poorer patient survival
and more complications than those without diabetes mellitus of similar
age. Strict control of blood pressure and careful monitoring for cardiac
disease and cerebrovascular accident should be required in diabetic
patients during hemodialysis.
Clinical study of diabetic nephropathy in NIDL)M patients. J.H. Shin,
H.S. Kim, Y.K. Kim, K.H. Choi, S.K. Ha, H.Y. Lee, D.S. Han, H,C.
Lee, and K.B. Huh, Department of Internal Medicine, Yonsei Univer-
sity, College of Medicine, Korea. Diabetic nephropathy is one of the
chronic vascular complications among diabetic patients which eventu-
ally progresses to ESRD, and also was reported as the leading cause of
ESRD. A total of 1192 NIDDM patients were studied. The clinical
characteristics and the prevalence of diabetic nephropathy (urinary
excretion of albumin 26-250 mg, or protein more than 500 mg without
any specific reason) and the concurrent complication such as hyperten-
sion, retinopathy and neuropathy, were examined in patients admitted
to Severance Hospital, Yonsei University from January 1985 to Decem-
ber 1989. The sex ratio was 1:1.08, and mean age was 55.0 10.7years.
The average duration of NIDDM was 6.5 6.5 years; non-obese type
was 903 (75.5%) cases and obese type was in 293 (24.5%) cases.
Microalbuniinuria and proteinuria occurred in 195 (16.3%) and 93
(7.8%) cases each, and chronic renal failure was found in 97 (8.1%)
1448
Abstracts 1449
cases. Grouping the duration of NIDDM by less than 5 years, 5—9,
10—14, 15—19, 20—24 years, the incidence of microalbuminuria was 73
(12.6%), 44 (17.0%), 41(21.8%), 19 (21.6%), 13 (21.0%) cases each,
respectively, and proteinuna was 21(4.7%), 20 (7.7%), 23 (12.2%), 11
(12.5%), 16(25.8%) cases, which revealed a longer duration of NIDDM
and a higher incidence of microalbuminuria and proteinuria. The
incidence of chronic renal failure by grouping the duration 5 years each
was: 27 (4.7%), 13 (5.0%), 24 (12.8%), 20 (22.7%), 10 (16.1%) cases.
Neuropathy, retinopathy, hypertension were observed in 60.4%,
37.8%, 7.1% each in diabetic nephropathy patients (288 cases). In
conclusion, the prevalence of diabetic nephropathy of NIDDM patients
was 32.2%, and the longer duration in NIDDM the higher the incidence
noted. Neuropathy was the complication most associated with diabetic
nephropathy.
Peripheral nerve conduction velocity in diabetic nephropathy. J.S.
Kim, J.H. Ahn, T.W. Lee, C.G. ihm, and M.J. Kim, Department of
Internal Medicine, Kyung Hee University School of Medicine, Seoul,
Korea. We measured peroneal and sural nerve conduction velocities to
evaluate the relation of the peripheral neuropathy to nephropathy in
diabetic patients with or without renal insufficiency. The results were as
follows: (1.) the peroneal nerve conduction velocities in the normal
renal function group (33.36 4.23 m/sec) and renal insufficiency group
(31.86 4.11 m/sec) with nephropathy tended to be lower than those of
the diabetic group without nephropathy (each P = 0.214, P 0.15). (2.)
There was no significant difference in peroneal nerve conduction
velocity between the normal renal function group and renal insuffi-
ciency group with diabetic nephropathy. (3.) The sural nerve conduc-
tion velocities in the normal renal function group (14.78 5.45 m/sec)
and renal insufficiency group (13.3 6.85 mlsec) with diabetic nephrop-
athy were significantly lower than those of the diabetic group without
nephropathy (each P < 0.001, P  0.01). (4.) There was no significant
difference in sural nerve conduction velocity between normal renal
function group and renal insufficiency group of diabetic nephropathy.
These data suggest that the frequency of the peripheral neuropathy,
especially sensory nerve, is high in diabetics complicated by nephrop-
athy whether they are in renal insufficiency or not.
Serum lipid, lipoprotein and apolipoprotein in diabetic nephropathy.
Y. Hwang, J.H. Ahn, T. W. Lee, C.G. Ihm, M.J. Kim, Department of
internal Medicine, Kyung Hee University School of Medicine, Korea.
It is known that 30—40 percent of diabetics have hyperlipidemia and that
cardiovascular complications which have been known to be the major
cause of death in diabetics occur by the abnormality in lipid metabo-
lism. We compared the concentrations of lipid, lipoprotein and apolipo-
protein of non-insulin dependent diabetics with and those without renal
complication and subclassified the diabetics with renal complication
according to the severity of proteinuria and the serum creatinine levels.
The results are as follows: (1.) The concentrations of total lipid (685.4
212.1 mg/dl vs. 576.1 75.7 mg/dl), cholesterol (193.5 75.5 mg/dl vs.
169.4 38.2 mg/dl), triglyceride (194,5 108.1 mgldl vs. 160.2 46.5
mg/dl), f3-lipoprotein (396.1 119.8 mg/dl vs. 94.5 29.3 mg/dI), LDL
(128.9 63.5 mgldl vs. 108.9 27.6 mg/dl) and VLDL (19.5 11.5
mgldl vs. 12.3 3.8 mg/dl) were significantly higher in diabetics (N =
43) than in the control (N = 19). (2.) The concentrations of cholesterol
(306.5 105.1 mg/dl vs. 193.5 75.5 mg/dl) and /3-lipoprotein (419.1
119.5 mg/dl vs. 396.5 119.6 mg/dl) were significantly higher in patients
with diabetic nephropathy (N = 14) than in those without it (N = 43).
(3.) There were no significant differences in the profiles of serum lipid,
lipoprotein and apolipoprotein according to the severity of proteinuria
in the diabetic nephropathy. (4.) The concentration of serum HDL was
significantly lower in the diabetic nephropathy group whose serum
creatinine levels were more than 2 mg/dl (N = 3) than in those whose
serum creatinine levels were less than 2 mg/dl (N = 4). (5.) There were
no significant difference in the profiles of serum lipids, lipoproteins and
apolipoproteins according to the serum creatinine levels in the diabetic
nephropathy group whose proteinuria was more than 3.0 g/day (N 7).
Effects of gout and hyperuricemia on renal function. K.H. Sung, K. W.
Kang, C.H. Park, H.C. Park, and C.M. Kang, Department of Internal
Medicine, College of Medicine Hanyang University, Seoul, Korea. We
analyzed 54 gout patients who have suffered gout for 10 years to prove
the cause of renal failure in gout nephropathy is not hyperuricemia, but
predisposing factors such as age, hypertension, atherosclerosis, infec-
tion, nephrocalcinosis, and intrinsic renal disease such as glomerulone-
phritis. The results are as follows: (1.) Incidence of proteinuria was seen
to be greater in patients with a low glomerular filtration rate, being 100%
in those with a GFR below 10 mllmin, 77.3% with a GFR between 10—30
mI/mm, 85.7% with a GFR between 30—50 mllmin, 0% with a GFR
above 50 mI/mm. (2.) There was a modest correlation between the
incidence of proteinuria and age. Proteinuria occurred in 0% of those
aged below 40 years, 25% of those aged 40 to 49, 64.3% of those aged
50 to 59, 58.8% of those aged 60 to 69, 70% of those aged 70 to 79 years.
(3.) Tophi were more frequently observed in subjects with a low GFR,
being 40% with a GFR below 10 mI/mm, 27.3% with a GFR 10—30
mI/mm, 28.6% with a GFR 30—50 ml/min, 42.9% with a GFR 50—80
mI/mm and 0% with a GFR above 80 mI/mm. (4.) U urate * V greater
than 800 g/min (excessive U urate V) occurred more frequently in
those with a plasma urate concentration of 9 mg/lOO ml or above. (5.)
The incidence of excessive U urate V was greater in the younger age
groups and proteinuria did not occur frequently in the excessive U urate
V group. (6.) Tophi were seen to be more frequent in patients with a low
glomerular filtration rate, being 20% with a GFR below 10 mg/mm,
22.7% with a GFR between 10—30 mI/mm, 14.3% with a GFR between
30—80 mI/mm, and 0% with a GFR above 80 mI/mm. (7.) Hyperuricemia
alone did not adversely affect renal function in patients with gout. The
following factors importantly correlated with nephropathy in gout:
cardiovascular disease, notably hypertension and atherosclerosis, with
nephrocalcmnosis and urinary tract infection (UTI). (8.) The predispos-
ing factors of gout nephropathy were hypertension, atherosclerosis,
UTI, and nephrocalcinosis; we could not find a predisposing factor in
two cases. The mean interval from first gout attack to gout nephropathy
was 15.4 years. (9.) In comparison with gout nephropathy and second-
ary gout, males were predominant in each group. The mean age of gout
nephropathy patients was 56.1 years and that of secondary gout was 42
years. The number of attacks and ESRD were higher in gout nephrop-
athy; tophi were not found in secondary gout.
Urolithiasis in abnormalities of uric acid metabolism. K.T. Sung, and
J.B. Yoon, Department of Urology, College of Medicine, Pusan Na-
tional University, Pusan, Korea. The level of serum uric acid and 24
hours' urinary excretion of uric acid was measured in 695 upper urinary
stone formers who were admitted to our department from 1979 to 1990.
Of 695 cases, 126 were shown to have uric acid abnormalities in serum
and/or 24 hour urine. For the prevention of recurrent stone formation,
allopurinol and sodium bicarbonate were administered to the stone
formers with hyperuricemia and/or hyperuricosuria. The results are as
follows: (1.) Of 126 cases with uric acid abnormalities in serum and/or
24 hours urine, type I (normouricemic hyperuricosuria) was in 73 cases,
type II (hyperuricemic hyperuricosuria) in 17 cases and type III
(hyperuricemic normouricosuria) in 36 cases. (2.) Of 126 cases, 31 who
were administered allopurinol (100—300 mg/day) and sodium bicarbon-
ate (3—9 g/day) after lithotomy had no recurrent stone formation for an
average of 14 months' observation. (3.) 126 cases with hyperuricemia
and/or hyperuricosuria were completely returned to normal range of
these values after administration of allopurinol and sodium bicarbonate
for 2 months on average. These results suggested that allopurinol and
sodium bicarbonate is effective in prevention of upper urinary stone
formation with hyperuncemia and/or hyperuricosuria.
An oral calcium tolerance test for the diagnosis of hypercalciuria in
patients with calcium nephrolithiasis. J.J. Lee, and J.B. Yoon, Depart-
ment of Urology, College of Medicine, Pusan National University,
Pusan, Korea. Hypercalciuria is the most common metabolic abnor-
mality in patients with calcium nephrolithiasis, and an oral calcium
tolerance test (OCTT) has been developed to diagnose various forms of
hypercalciuria. Seventy-one patients with calcium nephrolithiasis were
studied for urinary calcium excretion by OCTT thus constituting a
rigorous calcium restriction for 3 days, in conjunction with fasting and
calcium loading. The results are as follows: (1.) Of the 71 patients,
hypercalciuria was found in 43 cases (61%) and hyperuricosuria in 24
cases (33.8%). Hyperuricosuna was found more frequently in patients
with hypercalciuria than in patients with normocalciuria. (2.) Of 43
cases with hypercalciuria, 11 cases (15%) were classified as absorptive
type I, 14 cases (20%) as absorptive type II, 9 cases (13%) as renal
hypercalciuria, and 3 cases (4%) as primary hyperparathyroidism. In
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other 6 cases, the etiology of the hypercalciuria could not be defined by
our simple OCTf. (3.) In fasting, urinary Ca/Cr ratio was 0,052 0.025
in the normocalciuria group, 0.068 0.018 in absorptive type I, 0.068
0.025 in absorptive type II group, and all these values were within the
normal limit. In the renal hypercalciuria and primary hyperparathyroid-
ism group, the ratio was 0.167 0.033 and 0.149 0.029, and these
values were significantly higher than the normal range. (4.) After
calcium loading, urinary Ca/Cr ratio was 0.105 0.041 in the normo-
calciuria group, but in the hypercalciuria groups, the ratios were
markedly increased to 0.244 0.035 in absorptive type I, 0.288 0.042
in absorptive type II, 0.262 0.068 in renal hypercalciuria, 0.290
0.041 in the primary hyperparathyroidism group. (5.) In renal hypercal-
ciuria, the ratio of renal calcium reabsorption was 97.8 0.9%, and
tended to be lower than other subgroups of the hypercalciuria and
normocalciuria group. The ratio of renal phosphorus reabsorption did
not show the difference of the values among the subgroups of the
hypercalciuria and normocalciuria group. OCTT using rigorous calcium
restriction for 3 days is recommended as a relatively simple and reliable
method of defining the etiology of hypercalciuria.
Changes of serum 25-hydroxyvitamin D in children with nephrotic
syndrome. C.W. Ko, and J.H. Koo, Department of Pediatrics, Kyung-
pook University Hospital, Taegu, Korea. A prospective study was
conducted to evaluate changes of serum calcium and vitamin D in
children with nephrotic syndrome. Study patients consisted of 23
nephrotic children admitted to Kyungpook University Hospital from
January to December, 1990. The control group consisted of 10 healthy
children aged 4 to 14 years. The following results were obtained. During
relapse period of nephrotic syndrome, serum levels of total calcium
were 7.9 0.8 mg/dl, and this value was significantly lower than control
value of 9.5 0.5. it rose to 8.5 0.7 on the early remission days, and
9.2 0.8 mg/dl 1 month after remission. Blood levels of ionized calcium
were 3.4 0.4 mg/dl during relapse, and this value was also signifi-
cantly lower than control value of 4.1 0.4. It rose to 4.1 0.6 mg/dl
one month after remission. Serum levels of 25-hydroxyvitamin D
(25-HCC) were 4.2 2.9 ng/mJ during relapse, and this value was
significantly lower than that of control. It rose to 8.4 10.8 on the
remission day, and 11.8 5.3 ng/ml 1 month after remission. There was
inverse correlation (r =
—0.43, P <0.05) between levels of 25-HCC and
24hour urinary protein excretion and direct relation with serum albu-
min (r = 0.80, P < 0.001). Blood level of parathyroid hormone showed
no significant change. In conclusion, it can be said that hypocalcemia in
children with nephrotic syndrome is caused not only by lowered serum
albumin but also by low serum 25-HCC.
Clinical usefulness of transtubular potassium concentration gradient
(TTKG) in differential diagnosis of hypokalemia. D.W. Chae, R.H.
Cheon, Y.C. Lee, J. W. Roh, and H. Y. Oh, Department of Internal
Medicine, Hallym University, Korea. Urine potassium concentration
(UK) has been used in differential diagnosis of hypokalemia. But UK is
influenced by water reabsorption in meduliary collecting duct and
serum potassium concentration (SK) as well as by potassium secretion
in distal cortical nephron. In addition UK has a limited diagnostic value
in the range of 20-40 mEq/liter. TTKG is a newly introduced concept to
evaluate potassium secretion in distal cortical nephron using UK, SK,
and serum and urine osmolarity. To evaluate the clinical usefulness of
TTKG in differential diagnosis of hypokalemia, we measured TTKG in
25 normokalemic and 14 hypokalemic patients. The following results
were obtained: (1) Whereas TTKG had no relationship with SK, plasma
renin activity, or serum aldosterone concentration, it had a good
relationship with UK in both normo- and hypokalemic patients despite
the fact that both UK and SK were included in calculation formula of
UKG. (2) Whereas there was no difference in UK between normo- and
hypokalemic patients, TTKG was greater in patients with hypokalemia
due to inappropriate renal potassium loss than in normokalemic patients
(16.47 + 6.99 in patients with renal potassium loss and 4.80 + 0.49 in
normokalemic patients). (3) TTKG could differentiate 7 patients with
inappropriate renal potassium loss whose UK were between 20 and 40
mEq/liter.
Determinants of magnitude of pseudohyperkatemia in thrombocytosis.
Hf. Kim, C.H. Chung, CO. Moon, C.G. Park, S.F. Hong, M.S. Oh,
and H.J. Carroll, Department of Internal Medicine, College of Medi-
cine, Chosun University, Kwang/u, Korea, and Department of Medi-
cine, SUNY, Health Science Center at Brooklyn, New York, USA. The
release of potassium from platelets is a well-known cause of pseudo-
hyperkalemia in thrombocytosis. In predicting the magnitude of
pseudohyperkalemia associated with thrombocytosis, previous investi-
gations considered only the amount of potassium released from plate-
lets during blood clotting; although the increment in serum potassium
during blood clotting depends on the quantity of potassium released
from platelets as well as the volume of distribution of the released
potassium, which is inversely proportionate to the magnitude of in-
crease in serum potassium during blood clotting, and accuracy of this
formula has been tested in a patient with thrombocytosis.
A study of anion gap, serum sodium, and arterial p!1 associated with
hypoatbuminemia. W.J. Kim, K.S. Chang, C.O. Moon, and H.J. Kim,
Department of internal Medicine, College of Medicine, Chosun Uni-
versity, Kwangju, Korea. Thirty-one patients with hypoalbuminemia
(serum albumin 3.1) subdivided according to underlying diseases:
group I, nephrotic syndrome; group 2, liver cirrhosis; group 3, other
chronic diseases, and 17 healthy control subjects (serum albumin > 4.0)
designated as group 4 were studied to explore the degree and correla-
tion of decrease anion gap calculated as Na- (Cl + HCO3), hypona-
tremia and alkalemia associated with hypoalbuminemia. The mean
serum albumin level, mean anion gap, mean serum sodium concentra-
tion and mean pH in each subgroup were 2.2 0.8, 9.3 1.9, 139 2.5
and 7.43 0.05 in group 1,2.3 0,3, 9.6 1.6, 134 2.3, and 7.46
0.O3ingroup2,2.8 0.1,8.5 3.9, 136 3.4and7.46 0.O4ingroup
3, and 5.0 0.5, 13.1 1.5, 142 4.7 and 7.41 0.02 in group 4,
respectively, with statistically significance in decreased mean of anion
gap and serum sodium concentration (P < 0.05), and increased mean of
arterial pH (P < 0.05) in every subgroup but serum sodium and arterial
pH in group I when compared to control group (subgroup 4). In all 48
patients, a statistical significant correlation was found between the
anion gap and individual serum albumin (r = +0.62, P < 0.001), and
between serum sodium and individual serum albumin (r = +0.57, P <
0.001) with no correlation between the anion gap and serum sodium as
well as the anion gap and arterial pH.
Effectiveness of glomerular filtration rate using 51Cr.EDTA clearance
to evaluate hyperfiltration. S.B. Kim, K.H. Choi, S.K. Park, D.H.
Moon, M.H. Lee, K.U. Lee, J.S. Park, and C.D. Hong, Department of
Internal Medicine and Nuclear Medicine, Ulsan University, School of
Medicine, Seoul, Korea. Measurement of GFR using 51Cr-EDTA has
been known to be simple, precise and accurate. We measured CEDTA
using both 51Cr-EDTA (CEUTA) and creatinine clearance (Car) in 116
patients who were admitted or visited Asan Medical Center. To
measure GFR with 51Cr-EDTA, 50 Ci of 51Cr-EDTA was injected and
plasma sampling was done 3 and 5 hours after injection. The coefficient
of variation was 11.0 8.6% (mean SD) in 19 patients with repeated
GFR measurements and 22.8 12.3% in 13 patients with repeated Cr
measurements (P < 0.05). Correlation coefficient (R) between CEOTA
and estimated creatinine clearance was 0.697 (P = 0.0001) and that
between CEDTA and Cr was 0.9 (P = 0.0001). In 44 patients with CEOTA
less than 75 mI/mm, correlation coefficient between Ccr and CEDTA was
0.934 (P 0.0001) and that in 72 patients with CEDTA over than 75
mi/mm was 0.4 (P = 0.0005). The ratio of CCr/CEDTA related to the
degree of renal function was 1.32 0.72 in patients with CEOTA less
than 30 mI/mm, 1.11 0.25 in patients with CEOTA between 30 and 75
mI/mm, 0.97 0.20 in patients with CEDTA between 75 and 120 mI/mm,
0.76 0.18 in patients with CEDTA over 120 mI/mm. Out of 39 patients
with DM with CEDTA over than 75 mI/mm, 28 patients showed CEDTA
over 120 mi/mm, however, out of 33 patients with non-DM with CEOTA
over 75 mI/mm, only 13 patients showed CEDTA over 120 mI/mm (P =
0.0001). Out of 42 patients with CEDTA over 120 mllmin, mean of CEOTA
in patients with DM was 146.1 21.4 mI/mm and that in patients with
non-DM was 132.5 7.2 mI/mm (P < 0.05). These data highly suggest
that measurement of GFR using 51Cr-EDTA is more precise than that
using creatinine clearance and effective to evaluate hyperfiltration
because creatinine clearance underestimates GFR in the range of
CEDTA over 120 mI/mm. Degree and frequency of hyperfiltration is
greater in patients with DM than those with non-DM.
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Effects of cyclosporine on the vascular responsiveness and renin release
from the kidney. K.C. Choi, J. Lee, K. W. Cho, S.H. Eum, Y.S. Park,
and Y.J. Kang, Department of Internal Medicine and Physiology,
Chonnam University Medical School, Kwangju 501-190, Korea. The
present study was aimed to learn the effects of cyclosporine on the
vascular responsiveness to various vasoconstrictor and dilator agents
and on the renin release from the kidney. Male rats (Sprague-Dawley,
200—250 g) were treated with cyclosporine for either 1 or 3 weeks (10
mg/kg/day, i.m.) and thoracic aorta and both kidneys were removed.
Isolated aortic rings were suspended in the tissue chamber and exam-
ined in terms of their changes in isometric tension. Cortical slices were
prepared from the left kidney and renin release was measured while
they were kept at 37°C and continuously supplied with oxygen. Cortical
slice homogenate was prepared from the right kidney to measure its
renin content. The results obtained were as follows: (I.) The three-
week-treated group did not show significant differences in systolic
blood pressure, heart rate and plasma concentrations of Na and K
compared with the control group treated with vehicle without cyclo-
sponne. (2.) The maximum tension developed by the cumulative doses
of either phenylephrine or endothelin was lower in cyclosporine-treated
groups than in the control group, the three-week-treated group showing
lower value than the one-week-treated group. (3.) The magnitude of
relaxation due to acetyicholine of phenylephrine-precontracted aortic
ring was reduced by the cyclosporine treatment. The relaxation re-
sponse of the three-week-treated group was almost identical to that of
the endothelium-removed preparation. (4.) The relaxation response to
neither nitroprusside nor ANP was affected by the cyclosporine treat-
ment. (5.) The three-week-treated group showed significantly higher
values in plasma renin concentration, renal renin content and rerun
release rate of the cortical slice in the incubation media than the control
group. No significant difference was noted in plasma atrial natriuretic
peptide concentration, however. These results indicate that cyclospo-
rine attenuates the endothelium-dependent relaxation of vascular prep-
arations and increases renin storage and release in the kidney.
Cyclosporine toxicity on cultured human renal proximal tubular cells.
J. Y. Lee, Department of Pathology, Catholic University Medical
College, Seoul, Korea. Nephrotoxicity is the most common dose-
limiting factor of cyclosporin A (CsA) in clinical usage. But the
mechanism of CsA-induced nephrotoxicity still remains unresolved.
Many authors insisted that CsA-induced renal proximal tubular cell
injury is due to the secondary effects following hemodynamic changes
or endothelial cell damage, instead of direct toxicity by CsA. To find out
that CsA has a direct toxicity to the proximal tubular cells, the author
used primary cultures of human proximal tubular cells to eliminate the
hemodynamic or endotothelial influences that could be produced in the
in vivo model. In the present study, the viability against CsA was tested
by the neutral red assay method with modulation of Ca2 amount in
incubating media and observed electron microscopically. The viability
test showed direct toxic effect of CsA on human proximal tubular cells
and this was enhanced by Ca2 depletion in incubating media. Morpho-
logically noted are accumulation of lipid droplets and polyribosomal
dispersion, which may be associated with inhibition of cellular synthetic
activity. These results suggest the toxicity is a direct effect of cyclo-
sporine and that toxic mechanism may be due to inhibition of cellular
synthetic activity. This experiment also showed that primary cultures of
human renal proximal tubular cells can be good in vitro models for
investigating CsA nephrotoxicity.
Kinetics of cyclosporine uptake on cultured human proximal tubular
cells. J. Y. Lee, Department of Pathology, Catholic University Medical
College, Seoul, Korea. Cyclosporin A (CsA), a lipophilic cyclic unde-
capeptide, it not accumulated evenly in all tissues and has a high affinity
to several tissues such as lymphoid organs, liver, and kidneys. From
this point of view, it is reasonable to assume that the amount of CsA
uptake would be correlated with the extent of cell injury. On the other
hand, verapamil, a Ca2 channel blocker, has been shown to ameliorate
CsA nephrotoxicity. Since proximal tubule is the major site of drug
transport and CsA toxicity, the author has studied the nature of CsA
uptake and its interaction with verapamil in isolated human renal
proximal tubular cells. The CsA uptake pattern showed rapid increase
over the first 5 minutes and then achieved almost steady-state after 10
minutes at all concentrations (0.5—10 SM). And the Ca2 free state in
media-enhanced CsA uptake significantly, but there was no difference
between the uptake of 2.5 m and normal (1.8 mM) Ca2 levels in the
media. Kinetic analysis yielded that the Km and Vm values of
cyclosporine were 5. 6 M and 86.2 p mol/g cell protein/mm, respec-
tively. And verapamil (0.5 and 1 M) reduced CsA uptake significantly
(82 and 42% of control, respectively). But A2 3187 had no effect on CsA
uptake. These results suggest that the calcium channels and CsA
transporting sites on cell membrane are closely associated, and that Ca
and CsA might be uptaken competitively by proximal tubular cells.
Effect of cadmium intoxication on renal phosphate transport system in
rats. D.W. Ahn and Y.S. Park, Department of Physiology, Kosin
Medical College, Pusan, Korea. Effect of cadmium intoxication on the
renal cortical phosphate transport system was studied in adult male
Sprague-Dawley rats. Subcutaneous injections of CdCl2 at a dose of 2
mg Cd/kg body weight per day for 2 weeks induced marked polyuria,
glycosuria, proteinuria and phosphaturia, which are the characteristics
of chronic cadmium intoxication. In the renal cortical brush-border
membrane vesicles prepared from cadmium-intoxicated rats, the Nap-
dependent phosphate uptake was markedly attenuated, whereas the
Na-independent uptake was not apparently altered. These results
indicate that cadmium intoxication impairs the Na-phosphate cotrans-
port system in the brush border membrane of renal proximal tubular
cells, which leads to phosphaturia in intact animals.
Transport kinetics of glucose and alanine in renal brush-border mem-
brane vesicles of cadmium-intoxicated rabbits. Y.S. Park, H. Y. Lee, and
KR. Kim, Department of Physiology, Kosin Medical College, Pusan,
Korea. Changes in transport kinetics of D-glucose and L-alanine were
studied in renal luminal membrane vesicles isolated from cadmium-
intoxicated rabbits. Cadmium intoxication was induced by subcutane-
ous injections of CdCI2 at a dose of 2 mg Cd/kg day for 2—3 weeks.
Brush-border membrane vesicles were prepared from renal outer cortex
and outer medulla by Percoll gradient centrifugation. Cadmium intoxi-
cation resulted in a marked attenuation of Na -dependent transports of
D-glucose and L-alanine in both outer cortical and outer medullary
brush-border membrane vesicles, and this was due to reduction in 'max
and not Km. Similar results were obtained in normal vesicles directly
exposed to free cadmium. These results suggest that in long-term
cadmium-exposed animals free cadmium ions liberated in the proximal
tubular cytoplasm may directly impair brush border membrane thereby
reducing capacity of Na-dependent transport systems for glucose and
amino acids.
Additional effects of trifluoperazine and allopurinol in renal ischemic
injury of rats. H.S. Kwon, C.O. Moon, H.J. Kim, Department of
Medicine, College of Medicine, Chosun University, Kwang-Ju, Korea.
Effects of combined pretreatment of allopurinol (30 mg/kg) and trifluo-
perazine (2 mg/kg) in renal ischemic injury were investigated in rat
kidneys reflowed for 15 minutes after 1 hour ischemia. Malondialde-
hyde (MDA); superoxide dismutase (SOD) and catalase were measured
as indicators of oxygen radical induced injuries. MDA in the group of
combined pretreatments and the group of intact controls was almost
same; and more protective than that of separative treatments. SOD in
reflowed kidneys was decreased by about half respective to the intact
controlled group, and combined pretreatments showed more protective
effects. Catalase in reflowed kidneys was also decreased by about half
respective to the intact controlled group, and more protective effects in
combined pretreated group. As a result, it is concluded that allopurinol
as a xanthine oxidase inhibitor and trifluoperazine as a calcium antag-
onist have additive effects against injuries in reflowed rat kidneys.
Rhabdomyolysis.induced acute renal failure. S.H. Shin, M.S. Jeong,
S.K. Rhee, G. W. Yi, and Y. T. Shin, Department of Internal Medicine,
College of Medicine Chungnam National University, Daejeon, Korea.
Rhabdomyolysis has been reported as one of the causes of acute renal
failure. Rhabdomyolysis and myoglobinuria are often due to extensive
trauma with crush injuries, but nontraumatic rhabdomyolysis can also
be associated with increased muscle oxygen consumption, decreased
muscle energy production, muscle ischemia, infection, and direct toxin.
We evaluated the patients with rhabdomyolysis-induced acute renal
failure admitted to Chungnam National University Hospital from Feb-
ruary, 1982 to March, 1991, retrospectively. Rhabdomyolysis-induced
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acute renal failure is defined as acute renal failure with increased serum
muscle enzyme (CPK, LDH, GOT), positive orthotoluidine test on
urine examination and/or increased serum and urine myoglobin level,
and it was noted in 14 cases. The results were as follows: The causes of
14 cases were snake bite (5 cases), CO poisoning (3 cases), tetanus (2
cases), exercise (1 case), seizure (1 case), heat stroke (I case) and crush
injury (I case). Nine of fourteen patients with ARF due to rhabdomy-
olysis recovered completely after conservative management and/or
hemodialysis. Four patients died from extra-renal causes during oliguric
stage and one patient died from asphyxia after improvement of renal
function. All 5 patients who died were managed with hemodialysis: two
patients with tetanus and one patient each with snake bite, heat stroke
and crush injury.
The effects of glucose, insulin and somatostatin on glomerular mesaii-
gial cells (MC) to proliferate and produce collagen. CAL ihm, J.K. Park,
J.H. Ahn, T. W. Lee and M.J. Kim, Department of internal Medicine,
Kyunghee University, School of Medicine, Seoul, Korea. Glomerutar
MC produce extracellular matrix (ECM) components such as collagen,
the dysregulation of which may be related to the development of
mesangial expansion and/or glomeruloscierosis. The most significant
renal lesion of diabetic nephropathy is mesangial expansion largely due
to the accumulation of ECM proteins. However, the initiating mecha-
nism to cause the accumulation of ECM remains uncertain. Also, it's
controversial whether high glucose (HG) or insulin deficiency exert the
main effect. The mitogenic action of insulin has been suggested to be a
contributing factor in the pathogenesis of diabetic angiopathy. Re-
cently, MC have been tried to be cultured in the presence of HG. Thus
studies have been undertaken to determine whether HG directly
stimulate cultured rat MC to proliferate and produce collagen and
whether this effect can be modulated by insulin and somatostatin.
Sixteen hours of exposure to HG (450 mg/dl) reduced HI thymidine
uptake by 27.4 15.4% (N = 5, P < 0.05), which was, however,
reverted toward normal with io M insulin above pharmacological
concentration, Collagen production was measured by [3H] proline
incorporation method during the first 24 hours. Collagen and non-
collagen production in cell layer and medium by MC were significantly
increased in cultures containing HG (N = 6, P C 0.05),which were not
suppressed with addition of high insulin concentration (HI, 3.3 >< 10
M). In contrast, collagen and non-collagen production in cultures
containing normal glucose (NO) and HI was the same as normal
control.
Cell layer Medium
Non- Non-
Group Collagen collagen Collagen collagen
Normal 3491 224 2783 214 30096 8016 21434 2432
control
HG 4053 324 3398 27& 38188 7463" 28226 3067"
HG + 4313 481" 3583 579k 34416 6984 32406 1959"
HI
NO + 3426 321 2751 400 29210 4051 22994 2281
HI
Data are expressed as (mean su) cpm/1 X l0 cell.
"Pc 0.05 vs. normal control and NO + HI
Also, there was a good correlation between collagen production and
insulin concentration below !0 at (r = 0.98, P C 0.05). However,
collagen production in cultures containing 10 at insulin above phar-
macological concentration was not different from normal control.
Somatostatin suppressed the increased production in medium (16%, P
c0.05) and in cell layer (9%, PC0.05). These results indicate that HO,
rather than insulin deficiency, directly stimulates the production of
collagen and non-collagen protein by MC and inhibits MC proliferation,
which may be pathogenic in the development of the accumulation of
ECM in diabetes. Moreover, these processes may be prevented in vivo
if plasma glucose levels can be normalized with high insulin dose
initially, while hyperinsulinemia may aggravate it in the state of
hyperglycemia. Also these may be mitigated by administration of
somatostatin.
Transforming growth factor-beta in urine of anti-giomerular basement
membrane disease in tbe rabbit. J. W. Noh, W. Y. Cho, Y.J. Kwon, H.K.
Kim, R.C. Wiggins and S.H. Phan, College of Medicine, Department
of internal Medicine, Division of Nephrology, Hallym University,
College of Medicine, Department of internal Medicine, Division of
Nephrology, Korea University, and School of Medicine, Department of
internal Medicine, Division of Nephrology, Department of Pathology,
University of Michigan. Transforming growth factor-beta (TOP-fl)
secreted from all animal cells is an important regulatory factor sup-
pressing abnormal growth and proliferation of cells in maintaining
normal tissue. Among many other functions of TOF-fi, it is also well
known that it plays an important role during collagen synthetic process,
so we can easily postulate that there should be close relationship
between TOP-fl production and fibrosis, the end stage of organ failure.
Authors sampled urines from each of 15 rabbits at scheduled time points
before and after inducing crescentic glomerulonephritis by subcutane-
ous injection of guinea pig IgO and complete Preund's adjuvant
accompanied by intravenous injection of guinea pig anti rabbit anti
glomerular basement membrane antibody. TOP-fl activity in the urine
was estimated by bio-immunoassay using anti-TGF-fl antibody. Mink
lung epithelial cell was used as a sensor system for detecting TOP-fl
antibody in the urine. Results were as follows: (1.) TOP-fl! is excreted
in urine of normal rabbits as well as rabbits with anti-OEM antibody
induced crescentic glomerulonephritis. (2.) The pattern of TOP-fl
activity in the urine at each time point was very much similar to that in
the acid-activated cortical supernatant. This indicates that TOP-fl
activity in urine may reflect total cortical TOP-fl production acid-
activated by physiologic low pH of urine and unknown mechanisms.
The use of fluorescein-conjugated lectin as a reagent for histochemical
studies on cortical tissues of normal rabbits and of rabbits with crescentic
giomerulonephritls Induced by anti-giomerular basement membrane an-
tibody. J.W. Noh, R.W. Chun, D.W. Chae, Y.C. Lee, H.Y. Oh, M.H.
Park, and R.C. Wiggins, School of Medicine, Department of internal
Medicine, Division of Nephrology, Hallym University, Choon Chon,
College of Medicine, Department of Pathology, Han Yang University,
Seoul, Korea; and School of Medicine, Department of Internal Medi-
cine, Division of Nephrology, University of Michigan, Ann Arbor, Mi,
U.S.A. Lectins are extracts, protein or glycoprotein in nature, from
beans and seeds of many vegetables, but rarely from animal tissues.
Theyhave the ability to bind specific saccharides, so their binding is not
related with immune responses. The surface of animal cells is very rich
in glycoprotein and glycolipid. For this reason, lectins have been used
by some as a tool for histochemical studies on cells and tissue sections.
But there were few reports of lectin on renal tissue. Authors stained
cortical tissues of normal rabbits and rabbits with crescentic glomeru-
lonephritis induced by administration of anti-GBM antibody adminis-
tration with 14 kinds of fluorescein conjugated lectins. Results were as
follows: (1.) All cortical structures were positive to mannose/glucose
specific lectins. (2.) A number of dots were seen at periglomerular area
and interstitium, rarely in crescents and glomeruli by staining with Ulex
europeus I, Dolicho bitlorus, Succinylated WOA, Baleirarea symplifo-
ha lectin I. Sophora japonica agglutinin. These many dots were re-
garded as macrophages related with renal injuries and that possibility
was proved by staining of the same tissue sections with RAM 11
antibody, anti-rabbit macrophage antibody, in indirect immunofluores-
cent study. (3.) Crescent were stained only with mannose/glucose and
N-acetyl glucosamine specific lectins. This indicates that these two
sugar groups will be abundant in crescent.
Immunologic and morpbologlc study of experimental IgA nephropathy
in ddy mice after administration of cyeiosporin A (CyA). W. Y. Chung,
i.S. Lim, S. Y, Lee and S.K. Lee, Department of Pediatrics and
Pathology, College of Medicine, inje University, Department of Pa-
thology, Pusan National University, Pusan, Korea. ddy Mice have
been reported as a spontaneous animal model of IgA nephropathy after
40 weeks of age. To investigate the role of T-cells in the pathogenesis of
IgA nephropathy, we administered CsA (20 mg/kg) to 9-week-old ddy
mice intraperitoneally every other day until killed. Fifty ddy mice were
divided into 2 groups (grs) as natural course group (NCO) and CsA
injected group (CsAN). At 10, 17, 27 and 40 weeks of age, 5 ddy mice
of each gr were sacrificed. At 40 weeks of age, serum IgA level of both
grs were increased, and CD3+ and CD4+ T cells were increased in
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NCG but were markedly decreased in CyAN compared to those of 10
weeks of age. IN CsAN serum IgA level were lower than that of NCG.
Histological proliferation of mesangial cells with increased mesangial
matrix was observed in both grs but these changes were noted more
prominently and frequently in CsAN. IF and EM findings also revealed
the same results. These data suggest that decrease of CD4 + T-cell may
involve the inhibition of increase in serum IgA level, but it seems that
serum IgA level has no correlation with the histopathologic alterations
in aged ddy mice.
Effect of lovastatin on puromycin aminonucleoside-induced focal seg-
mental glomerulosclerosis in rats. M.J. Kim and I.J. Choi, Department
of Internal Medicine, Inha University College of Medicine, Inchon and
Department of Pathology, Yonsei University College of Medicine,
Seoul, Korea. Hyperlipidemia in patients with nephrotic syndrome has
long been recognized. The significance of the lipid abnormalities and
their potential role in the progression of renal disease have all been a
cause of debate. However, recent experimental and clinical studies
have indicated that hypercholesterolemia may be an independent risk
factor in the pathogenesis of focal segmental glomerulosclerosis (FSGS)
as it is in atherosclerosis. This study was undertaken to investigate the
possible relationship between hyperlipidemia and development of gb-
merulosclerosis by pharmacological intervention with lipid-lowering
agent lovastatin (LVST) and by Microfil perfusion into renal microves-
sels. The nephroptic syndrome was induced in uninephrectomized
Wistar rats by chronic administration of puromycin aminonucleoside
(PAN) and protamin sulfate (PS). Serial changes of urinary protein were
measured in rats at 14-day interval up to the 56th day; blood chemistry
and renal histology were obtained at the 28 and 56th days. Microfil
perfusions were performed in rats of each experimental group at final
sacrifice. Repeated injections of PAN and PS induced NS with massive
proteinuria and sustained hyperlipidemia, and light microscopic study
of kidney demonstrated progressive FSGS with tubulointerstitial
changes in short period. The LVST-treated rats had significantly lower
cholesterol and triglyceride, and lower BUN and creatinine than those
in the simple PAN-treated group at each periods. Both groups of rats
developed equivalent degrees of proteinuria and hypoalbuminemia.
Segmental glomerubosclerosis was induced and showed a significant
increase in the PAN-treated group. However, segmental glomerulo-
sclerosis was significantly prevented in the LVST-treated rats. Micro-
vascular pattern showed a more smoothly tapered and branching
preglomerular arteriole and nicely filled gbomerubi in the control group,
but there was an irregular and beaded appearance in the preglomerular
arteriole and multiple filling defects in glomeruli in the PAN-treated
group. In the lovastatin-treated group, those preglomerular changes and
segmental glomerular filling defects were significantly suppressed when
compared with those in the PAN-treated group. In conclusion, PAN-
induced segmental glomerulosclerosis could be ameliorated with lova-
statin by reduction of hyperlipidemia on histologic and microvascular
changes. This suggests that hyperlipidemia contributes to the pathogen-
esis of progressive glomerulosclerosis.
Studies on the role of interleukin-4 and FceR II in the pathogenesis of
minimal change nephrotic syndrome. B.S. Cho, C.!. Ahn, C.-E. Lee,
and K-H. Pyun, College of Medicine, Department of Pediatrics,
Kyung Hee University, Genetic Engineering Research Institute, KIST,
Seoul, Korea. Minimal change nephrotic syndrome (MCNS) has often
been associated with elevated IgE levels and involves immune dysfunc-
tion. We investigated the role of interleukin-4 (IL-4) in the pathogenesis
of MCNS through the regulation of membrane FceR II, low affinity
receptor for IgE, expressed on B-cells. A significant higher expression
of membrane FceR II was found on fresh B-cells of MCNS (N = 18)
than on those of normals, as analyzed by fluorescence activated cell
scanner by double antibody staining with anti-Leu 16 (PAN B marker)-
FITC and anti-Leu 20 (FceR II)-phycoerythrin. Sera from these pa-
tients also demonstrated increased IL-4 activity as compared with those
of normal subjects. We observed that nephrotic T-cells have a greater
ability (up to 9-fold) than normal cells to produce IL-4 as assayed by
B-cell proliferation and FcrR II expression. As in the case of normal
B-cells, nephrotic B-cells were likely to respond to IL-4 (5—100 U/mi) to
effectively induce FceR II expression (up to 6-fold). These results
suggest that MCNS may be a T-cell disorder involving abnormal
production of IL-4 and that the counter regulation of FceR II by IL-4
may play an important role in pathogenesis of MCNS.
Brush border deficiency of renal proximal tubule in idiopathic Fanconi
syndrome (clinicopathological correlation presentation). K.W. Ko, J.G.
Chi, H.S. Lee, and S.H. Kang, Department of Pediatrics, Pathology,
Seoul National University Children's Hospital, Seoul, Korea. Idio-
pathic Fanconi syndrome with hyperchioremic metabolic acidosis (ci
114 mEq/liter, pH 7.29, pCO2 16 mm Hg, HCO3 8 mEq/liter), renal
glycosuria (FBS 74 mg%, urine glucose(+++) with 796 mg%), hy-
pophosphatemic rickets (P 2.3 mg%, FE4 32.4%, flared, frayed and
cupped epiphyses of radius and ulna), hypouricemia (uric acid 2.0
mg%), hypokalemia with K wasting (2.9 mEq/liter, FEK 60.7%) and
renal aminoaciduria is manifested in a 3½ year old girl. Further work up
on functional study of renal tubule revealed proximal tubular acidosis,
evidenced by 21.2% of FEHcO3, 54mm Hg of (U-p)plo2 urine pH of 5.0.
In autopsy specimen of this patient, pronounced deficiency or lack of
brush border of renal proximal tubule and effaced microvilli as well as
segmental thickening of tubular membrane, hitherto unreported, were
found.
Clinical outcome of Henoch-Schönlein purpura nephritis in children.
J.S. Lee, M.G. Mi K.S. Pai, P. Kim, H.J. Jeong, and I.J. Choi,
Department of Pediatrics and Pathology, Yonsei University College of
Medicine, Seoul, Korea. One hundred patients with Henoch-Schonlein
purpura (HSP), admitted to the Department of Pediatrics, Severance
Hospital from 1978 to 1989, were analyzed with respect to clinical
outcome. Of the 100 HSP cases, 62 were male and 38 female, the mean
age at onset was 8.0 years, and the mean follow-up duration was 20
months. A percutaneous renal biopsy was performed in 65 cases, 42
male and 23 female, and the mean age at onset was 8.7 years and the
mean follow-up duration was 31 months. A study of the relationship
between the clinical outcome and several factors including sex, age at
onset, urinary findings on admission, clinical state (by Meadow and
Counahan) on admission, histopathological grade (by ISKDC) of first
biopsy, and treatment with or without prednisone was done. Outcome
was not related to sex and prednisone treatment. The groups of under
6 years of age, with normal urinary findings or microscopic hematuria
only, clinical state A, and histopathological grade I showed a signifi-
cantly higher incidence of outcome state A (P < 0.05). But groups with
other clinical presentations and histological grades did not have any
significant influence on the outcome. Follow-up biopsies were per-
formed in 10 cases with an interval of 6 months to 6 years and the results
showed improvement in 4, no change in 2, and aggravation in the
remaining 4 cases.
Clinicopathological association in IgA nephropathy. S.B Park, T.H.
Chung, S.H. Sohn, H.C. Kim, and K.K. Park, Department of Internal
Medicine, Department of Pathology, Keimyung University School of
Medicine, Taegu, Korea. We reviewed the clinical and histopatholog-
ical findings of 72 unselected patients with IgA nephropathy. The mean
age at initial biopsy was 27.9 years (32 males, 40 females). Clinical
manifestations showed 29 patients (40.3%) with gross hematuria, 17
patients (23.6%) with nephrotic syndrome, 16 patients (22.2%) with
asymptomatic urinary abnormality, 7 patients (9.7%) with acute gb-
merulonephritis and 3 patients with chronic gbomerubonephntis. Histo-
logical grading by Meadow et al showed grade I in 11.1%, grade II in
30.6%, grade III in 33.3%, grade IV in 20.8% and grade V in 4.2%. HBs
Ag was detected in 11 patients (15.3%) without active or chronic liver
disease. During the mean follow-up of 14.2 months, patients with mild
(grade I, II) lesions had a benign course without deterioration of renal
function, whereas eight out of 34 patients (24.2%) with moderate to
severe (grade III, IV & V) lesions developed chronic renal failure (P <
0.01). Four out of nine HBsAg positive patients (4-4.4%) developed
renal failure, whereas four out of 52 HBsAg negative patients (7.7%)
developed renal failure (P < 0.01). These observations suggest that
histologic grading of renal biopsies and hepatitis B virus antigenemia
may be poor prognostic indicators of the clinical outcome of IgA
nephropathy.
The clinical and pathologic features of hepatitis B virus-associated
gbomerulonephritis in adult patients. Y.G. Kim, W.S. Yang, J.K. Lee,
J.S. Han, S. Kim, J.S. Lee, Y.I. Kim, Seoul National University
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College of Medicine, Kangnam General Hospital, Public Corporation,
Seoul, Korea. Hepatitis B virus-associated glomerulonephritis (UN) is
now a well recognized entity and various glomerular diseases have been
described. But the majority of reported patients were children and
clinical and pathologic features in adult patients are not well known. So
we studied 179adult patients with UN who had HBsAg in the serum and
no evidence of other secondary UN between 1979 and 1989 at Seoul
National University Hospital. The male:female ratio was 4:1. The age
ranged from 15 to 67 years and peak incidence (35%) was noticed in the
age range of 30—39 years. Microscopic hematuria was observed in 70%
and nephrotic range proteinuria (>3.5 g/day) in 36% of patients. The
values for serum aspartate aminotransferase and alanine aminotrans-
ferase were normal in 58% and 65%, respectively. BUN and serum
creatinine values were normal in 80% and 60%, respectively. Serum C3
levels were reduced in 6% (10/165) C4 in 13% (21/164) and CH50 in 13%
(19/148). Serum IgA levels were increased (>350 mg/dl) in 29% (34/118)
and HBeAg was positive in 61% (86/141). Light microscopic findings
showed mesangial expansion in 65%, capillary loop thickening in 51%,
double contour in 38% and spikes in 20% of patients. Focal segmental
sclerosis and crescent formation was observed in 22% and 18% of
patients, respectively. Immunofluorescent findings of 145 patients
showed mesangial and/or capillary deposit of IgG in 66%, 1gM in 65%,
IgA in 54% and C3 in 81% of patients. Electron microscopic findings of
118 patients showed electron dense deposit in 91% (107/118) of patients
and mesangial deposit (89/118, 75%) was most frequent. Subendothelial
and subepithelial deposits were observed in 55% (65/118) and 48%
(57/118) of patients. Subepithelial deposits of 57 patients were associ-
atedwith subendothelial deposits in 74% (43/57) and mesangial deposits
in 75% (42/57) of patients.
Transport of phosphate by renal brush-border membrane vesicle
(BBMV) during development—Role of growth hormone. Y. Choi, H.!.
Cheong, and K. W. Ko, Department of Pediatrics, College of Medicine,
Seoul National University, Seoul, Korea. It is well documented that
plasma concentrations of phosphate (Pi) are higher in the developing
subject than the adult. In previous study, we demonstrated that Vmax of
Na-Pi cotransport mechanism of renal BBMV was higher in immature
than mature rats. In this study, we evaluated the role of growth
hormone (Gil) in the maintenance of higher Vmax observed in immature
rats. Methionyl-GH (Lucky Co.) was given 2 U/kg/day for 5 days to
immature (4—5 weeks) and mature (10—12 weeks) Sprague-Dawley rats.
Control rats received saline. BBMV preparations were obtained by Mg
precipitation method from superficial cortex and rapid filtration tech-
nique using 32Pi was performed for kinetic analysis of Na-Pi cotransport
mechanism. Both plasma Pi and TRPi were higher in immature rats. In
the mature rats, both plasma Pi and TRPi were increased by OH
treatment. On the other hand, those values were not changed by Gil
treatment in the immature rats. Km values were not different between
control and OH-treated rat BBMV in both immature and mature rats.
Vmn (pmol/mg protein at 10 seconds) of control immature-rat BBMV
was 3117 296.4 (mean Sc, N = 7) which was not different from that
of OH-treated immature rats (3198 138.8, N = 7). In the mature rats,
Vinax of control was 1744 118,5 (N = 8) which was increased to 3104
284.5 (N = 7) by GH treatment. With the above findings, it seems
likely that Gil has a significant role in the maintenance of higher Vmax
observed in immature animals. However, an experiment using OH-
inhibited and parathyroidectomized animals may be needed to confirm
the role ofGil in N reabsorption during development.
Clinical manifestations of Korean Hemorrhagic fever. Y. Kim, 0.-H.
Kim, Y, Chung, J.S. Han, S. Kim, J.S. Lee, Department of Internal
Medicine, College of Medicine, Seoul National University, Seoul,
Korea. After elucidation of the etiology and development of the
serologic diagnosis in Korean Hemorrhagic fever (KHF), cases of
atypical clinical features have been reported. To review recent clinical
manifestations of KHF, we have studied retrospectively the clinical
manifestations of 98 cases of 143 serologically confirmed KHF patients
who were admitted to Seoul National University Hospital (SNUH)
during the last five years. (1) Of 143 patients, 109 were male and 34 were
female (male:female = 3.2:1). Their age distribution was 42.4 14.5(mean SD) years-old. (2) All of the 98 cases had fever. The numbers
of patients who had chill, headache, eyeball pain and back pain were 84,
76, 38 and 64, respectively. The numbers of patients who had facial
flushing, conjunctival infection, petechiae and purpura were 51, 68, 62
and 23, respectively. (3) The maximal body temperature was 39.2
0.7°C, and the duration of fever was 4.2 2.3 days. Twenty-four
patients had hypotensive phase and sixty-six patients had oliguric phase
with duration of 7.2 3.4 days. The duration of diuretic phase was 11.7
5.3 days and the maximum urine volume was 5600 1800 mI/day.
There were four patients who had neither oliguria nor azotemia during
the course. Thirty-five patients had evidence of the disseminated
intravascular coagulation during their illness. Hemodialysis, 2.7 times
in average, were performed in 41 patients during the period of azotemia.
(4) Seventy-three patients out of 98 had the complications such as
hypertension, anemia, infection (urinary tract infection, pneumonia,
sepsis) and CNS complications (convulsion, CVA, coma), the numbers
of which were 45, 36, 19 and 11, respectively. Six patients had
pulmonary edema or pulmonary hemorrhage and three patients had
adult respiratory distress syndrome (ARDS). Nine patients were con-
firmed to have panhypopituitarism late in the course, and they all
needed hormonal replacement therapy. Besides, transient conduction
disturbances such as l°AV block, prolonged QT interval and AV
junctional arrhythmia were observed. Also, we observed the case with
acute glaucoma. (5) Of 98 patients, by the WHO severity criteria, 67
were mild, 19 moderate, and 12 severe. The severity scores were higher
in the cases with complications of anemia, infection, ARDS, pulmonary
hemorrhage, convulsion, or panhypopituitarism (P < 0.05). (6) Of 143
patients, 8 (male 6, female 2) died, and the mortality rate was 5.6%.
Four patients died during their hypotensive phase, three during oliguric
phase and one during diuretic phase. The causes of death were primary
shock (3), sepsis (4) and CVA (1). All of the mortality cases were
"severe" according to the above WHO criteria. The mortality rate was
related to the respiratory and the hepatic score (r = 0.70, r = 0.72
respectively, P < 0.05). Also it was higher in the cases with CNS
symptoms such as altered mentality, convulsion and CVA (P < 0.05).
In conclusion, complication rate and mortality of KHF patients admit-
ted to SNUH during the last five years were 74.5% and 5.6%, respec-
tively. The mortality and the clinical severity score were related to each
other (r = 0.71, P C 0.05).
Renal pathology findings in patients with hemorrhagic fever with renal
syndrome. H,S. Son, J.H. Ahn, T.W. Lee, C.G. Ihm, M.J. Kim,
Department of Internal Medicine, College of Medicine & Pathology,
Kyang Hee University, Seoul, Korea, Hemorrhagic fever with renal
syndrome is characterized by sudden onset of fever, chills, hemorrhagic
manifestations, and renal syndrome. The pathologic findings of kidneys
in patients with Hemorrhagic fever with renal syndrome are not clearly
defined. To evaluate the pathologic changes of the kidney in these
patients, renal biopsies were performed in diuretic phase. The following
results were obtained by the analysis of light microscopic, immunoflu-
orescence microscopic and electron microscopic findings. (I) Accord-
ing to the primary involved sites, renal biopsy findings could be
classified into three types.First, glomerular changes only were noted in
11 cases. Second, tubulointerstitial changes only were noted in 5 cases.
Third, glomerular changes with tubulointerstitial changes were noted in
I case. (2) Glomerular changes were as follows: On light microscopic
findings, mesangial cell proliferation and expansion of mesangial matrix
were observed in 9 cases, and nonspecific glomerular changes in 2
cases. On immunofiuorescence microscopic findings, diffuse granular
deposits in mesangium were noted in 7 cases. Ig A(+) and C3(-t-) was
noted in 2 cases, IgA(±), C3(±), and Clq(+) in 1 case, IgG(±), IgA(±)
and C3(±) in 1 case, IgA(±) and IgM(±) in I case, only lgM(±) in 1
case, only Clq(+) in 1 case. On electron microscopic findings, mesan-
gial cell proliferation and expansion of mesangial matrix were observed
in 9 cases, electron dense deposits in 4 cases, and segmental oblitera-
tion of foot processes and focal thickening of GBM in 4 cases. (3)
Tubulointerstitial changes were as follows: On light microscopic find-
ings, mild to moderate interstitial fibrosis with mononuclear cell infil-
tration were observed in 5 cases, and interstitial edema in 3 cases,
tubular necrosis and atrophy in all cases, but interstitial hemorrhage
was not noted. On immunofluorescence microscopic findings, no im-
munofluorescent substance was noted in tubular basement membrane
and interstitium, but in 3 cases only C3 granular deposits were exam-
ined along vascular walls. On electron microscopic findings, tubular
vacuolizations were observed in 3 cases, and infiltration of lymphocytes
and plasma cells with increased collagenous fibrous tissue in 2 cases. In
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conclusion, pathologic changes of the kidney were noted in glomeruli as
well as tubulointerstitium in patients with Hemorrhagic fever with renal
syndrome, and the most common change was glomerular changes
without tubulointerstitial changes. Therefore immune deposits in
mesangium and infiltration of mononuclear cells in interstitium suggest
that immune mechanism and/or direct cytotoxic effect might be impli-
cated in renal tissue injuries, and that basic studies for pathophysiology
will be needed.
Analysis of proteinuria using PHAST® system in HFRS. J.S. Song,
K.C. Kwak. D.J. Oh, C.H. Kim, B.J. Lee, F.T. Kang, Y.I. Cha, and
S.H. Yu, Department of internal Medicine, Clinical Pathology, Chung-
Ang University HFRS Center, Capital Army Hospital, Korea. Hemor-
rhagic fever with renal syndrome (HFRS) is an acute infectious disease
caused by Hantavirus and is characterized by fever, hemorrhage, and
variable degree of renal failure. Renal pathologic findings are mild
mesangial proliferation in glomeruli and severe destructive changes in
renal tubules and interstitium. Therefore, the differentiation of protein-
uria according to their molecular size as glomerular or tubular in HFRS
will provide important clues to know pathophysiologic mechanisms.
Between November, 1990 and January, 1991, we studied proteinuria of
patients with HFRS according to their days of illness and clinical phases
using PHAST® system. The results were as follows:
Table 1. Patterns of proteinuria according to their days of illness
Pattern day 2 4 6 8 10 12 14 16 18 20 22
MUSGT 1 6 12 3 1 1
MSGT 2 2
USG 1
SG I
Albuminuria 1 1 2 1 2 1 2
Negative 3 2 2 2 1 3
Table 2. Patterns of proteinuria according to clinical phases
Patterns Phases Febrile
Hypo-
tensive Oliguric Diuretic
Convales-
cent
MSUGT 11 5 11 8 1
MSGT 1 2 1 3
USG 1
SG 1
Albuminuria 1 7 4
Negative 2 2 1 6 7
Abbreviations are: MUSGT, mixed unselective glomerulotubular
proteinuria; MSGT, mixed selective glomerulotubular proteinuria;
USG, unselective glomerular proteinuria; SO, selective glomerular
proteinuria.
Our results suggest that glomerular and tubular lesions develop simul-
taneously, because of high incidence of mixed unselective glomerulo-
tubular proteinuria in the early clinical courses. The recovery of
glomerular lesion may be delayed more than that of tubular lesion,
because tubular proteinuria disappears earlier than glomerular protein-
uria in the late clinical courses.
Association between proteinuria and interleukin 2 in Hemorrhagic
fever with renal syndrome. Y.S. Kim, Y.J. Kwon, D.R. Cha, W. Y. Cho,
H.K. Kim, Department of internal Medicine, Korea University Hospi-
tal Seoul, Korea. Hemorrhagic fever with renal syndrome (HFRS) is a
disease caused by a virus which develops acute renal failure (ARF) and
severe proteinuria during clinical course. There are many controversies
about pathogenesis of disturbed renal function during its course, but it
largely remains unknown. Recently renal biopsy findings in HFRS
indicate that T lymphocytes infiltrated in renal interstitium may asso-
ciate with abnormal renal function and proteinuria. Therefore, for the
evaluation of T-cell dysfunction, we measured interleukin 2 (IL-2) in
serum and urine in oliguric and diuretic phase of patients who showed
typically clinical manifestation of HFRS and course of ARF. (1.) In
HFRS patients, 24 hour proteinuria in the oliguric phase (731.6 106.9
mg/dl) was significantly higher than in the diuretic phase (499.9 275.2
mg/dL; P = 0.0009) and also significantly higher than control group
(36.5 8.6 mg/dl; P = 0.0000). (2.) There was no significant difference
in serum IL-2 between oliguric and diuretic phase, but there was
significant difference compared with control group, respectively. (3.)
The measurement of urine IL-2 of HFRS patients in the oliguric phase
was significantly higher than patients in the diuretic phase (0.35 0.05
fmol/mgCr) and control group (0.78 0.27 fmollmgCr) (P < 0.05). (4.)
In oliguric phase of HFRS patients serum IL-2 and 24 hour proteinuria
showed linear relationship (r = 0.64,P = 0.09) and creatinine clearance
and urine IL-2 showed reverse relationship (r = 0.73, P = 0.04). With
the above results, we consider that pathophysiology of abnormal renal
function is associated with IL-2 secreted by T lymphocytes inifitrating
in renal interstitium and we also presume that IL-2 has certain effects in
proteinuria.
Plasma endothelin levels in patients with Korean Hemorrhagic fever.
Y.S. Yoon, C.W. Yang, S.J. An, Y.S. Kim, I.S. Park, S.Y. Kim, W.S.
Koo, E.J. Choi, Y.S. Chang, and B.K. Bang, Department of internal
Medicine, Catholic University Medical College, Seoul, Korea. Endo-
thelin (ET) is a potent vasoconstrictive peptide derived from endothelial
cells. To assess a role of ET in the development of acute renal failure,
we investigated plasma ET concentrations in sixteen patients with
Korean Hemorrhagic fever (16 men) whose ages ranges from 21 to 25
years (mean 22 years). The mean (± SD) plasma concentrations of
immunoreactive ET in the oliguric phase was 2.8 3.4 pg/mI, which is
a higher level than the normal one of 1.3 0.5 pg/mI (N = 8); it
significantly decreased during the diuretic phase, 0.8 0.7 pg/mI (P <
0.05; oligunc vs. diuretic). The declined levels of ET during the diuretic
phase recovered toward normal after the convalescent phase. How-
ever, there was no close correlation between ET and plasma renin
activity, atrial natriuretic peptide, and serum creatinine. In conclusion,
based on the above findings, it is suggested that ET may play an
important role in the development of acute renal failure in Korean
Hemorrhagic fever.
Recirculation in chronic maintenance hemodialysis. G.H. Kim, F.S.
Kim, H.J. Woo, K.C. Kwak, D.J. Oh, J.S. Song, F.T. Kang, and S.H.
Yu, Department of internal Medicine, Artificial Kidney Unit, Chung-
Ang University, Korea. Recirculation, the mixing phenomenon of
dialyzed and undialyzed blood during hemodialysis, occurs mainly in
single needle dialysis and partly in two needle dialysis. It decreases the
effectiveness of hemodialysis. The causes of recirculation are (1) the
lower fistula blood flow than that of the dialyzer. (2) the use of common
pathway or dead space for the blood entering and leaving the patient, (3)
small stroke volume per dialyzer cycle, and (4) the abnormal compli-
ance of extracorporeal circuit. The estimated recirculation is reported
up to 15—25%. We studied the recirculation in AVF and Goretex fistula
according to the dialyzer blood flow rate and distance between arterial
and venous line. The results are as follows: (1) Ten men and two women
were studied and their mean age was 39.4. (2) Their vascular access was
AVF in 10 and Goretex fistula in 3. The mean dialysis period was 27.6
months. (3) Calculated recirculation rate with BUN was 3%, 4%, 5%,
6%, and 8% when blood flow as 0, 100, 150, 200, and 250 mI/mm,
respectively. (4) Calculated recirculation rate with creatinine was 1%,
1%, 5%, 6%, 10% when blood flow as 0, 100, 150, 200, and 250 mI/mm,
respectively. (5) Significant differences in recirculation rate were found
between AVF and Goretex, the recirculation rate was 4%, 5%, 4%, 5%,
and 6% in AVF patients and 0.7%, 6%, 9%, 9%, and 18% in Goretex
patients when blood flow was 0, 150, 200, and 250 mI/mm, respectively.
(6) There was no relationship between blood flow and distance of
arterial and venous lines in the recirculation rate. In summary, the
calculated recirculation rate with BUN or creatinine can be a useful
indirect method to assess the function of vascular access.
Interferon production is defective in uremic HBsAg carrier. H.B. Lee,
C.S. Park, S. W. Cho, D.C. Han, and S.D. Hwang, Hyonam Kidney
Laboratory, Soon Chun Hyang University, Seoul, Korea. The chronic
HBsAg carrier state is particularly common among hemodialysis pa-
tients. To better understand the mechanisms that lead to the develop-
ment of the chronic carrier state we studied in vitro T-cell proliferative
responses to mitogens (PHA, anti-CD3, and combination of anti-CD2
9—1 and 9.6) and mitogen-induced interleukin 2 (IL-2) and 2'5'-oligoad-
enylate synthetase (2'5'-AS) production in 7 uremic asymptomatic
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HBsAg carriers (UC) and 3 control groups: 11 non-uremic asympto-
matic carriers (NC), 6 uremic responders (UR) and 12-non-uremic
responders (NR) to hepatitis B vaccine, IL-2 was measured by ELISA
method and 2'S'-AS by RIA. (1) The number of circulating lymphocytes
was significantly lower in UC than in NR and NC. There was no
difference between UC and UR. (2) Proliferative responses of PBMC
from UC were not different from those of the 3 control groups. (3) IL-2
production was significantly higher in PHA-stimulated than in unstim-
ulated cultures in all 4 groups. Both unstimulated and stimulated IL-2
production were significantly higher in NC, UR, and UC than in NR. (4)
2'S'-AS production was significantly greater in PHA-stimulated than in
unstimulated cultures in all 4 groups but was significantly lower in UC
than in NR or UR. No difference was observed between NC and UC. In
conclusion, it appears that the defect in interferon production may play
an important role in the development of chronic HBsAg carrier state in
uremia.
The survival rate and causes of death in patients with chronic renal
failure on hemodialysis. C.W. Suk, K.K. Woun, Y.D. Ho, and H.S.
long, Department of Internal Medicine, Soonchunhyang University,
Chunan Hospital, Korea. The survival rate and the causes of death
were analyzed in 109 patients with end-stage renal failure on hemodi-
alysis during a 6.5 year period, between June, 1984 and December,
1990, at Soonchunhyang Chunan Hospital. The survival rate was
analyzed by the life table method, and the relationship between death to
the age at first treatment of hemodialysis underlying disease and the
type of insurance were evaluated by chi-square test. Causes of death
showed cardiovascular disorders, including cerebrovascular diseases
and heart diseases, as the top primary causes of death (46.4%), followed
by inadequate dialysis (25%) and infection (14.3%). Early in the course
of hemodialysis, a significant proportion of patients died, However, for
the group as a whole, the survival rate showed a decrease as the
hemodialysis duration increased. The changes in the survival rate are as
follows: 92% for 0.5 year, 83% for 1 year, 81% for 1.5 year, 80% for 2
years and 78% for 3.5 years. Older patients and diabetic patients
showed a poorer outcome than patients whose total expenses for
dialysis were covered by the government, who showed a better prog-
nosis than the other patients.
End-stage renal failure In 124 children: Analysis of etiology, age and
interval from early renal failure to the end stage. K.S. Kim and W.E.
Grupe, Department of Pediatrics, KonKuk University College of Med-
icine, Seoul, Korea and State University of New York, New York, USA.
Of 268 children with chronic renal failure who were admitted to
Children's Hospital, 124 cases were followed completely to time of
dialysis. The primary renal diseases were as follows: Renal dysplasia
and/or hypoplasia (37 cases), focal segmental glomerulosclerosis (16
cases), obstructive uropathy (12 cases), membranoproliferative glomer-
ulonephritis (7 cases), chronic pyelonephritis (6 cases). The mean age of
early renal failure was 12 years; 20% of children with early renal failure
were younger than 5 years, 22% 5 to 10 years and 32% 10 to 15 years.
The mean age of end-stage renal failure was 12 years; 15% younger than
5 years, 17% 5 to 10 years, 37% 10 to 15 years and 31% older than 15
years. At the time of renal death, the serum creatinine level below 10
mg% was 89% of the children below 5 years, compared to 39% in the
patients older than 10 years. The mean interval from early renal failure
to terminal stage was 311/12 years in congenital and hereditary renal
diseases, I 1/2 years in acquired renal diseases, 3¼ years in renal
dysplasia, 51/s years in obstructive uropathy, 1¼ years in glomerulo-
nephropathies and 31/6 years in chronic pyelonephritis. In the glomeru-
lonephropathies, the nephrotic syndrome group showed no significant
differences in age, serum creatinine and the interval from primary
diagnosis to dialysis from the nephritis group. This study shows that the
most common causes of pediatric renal failure were renal dysplasia
and/or hypoplasia and focal segmental glomerulosclerosis. One-third of
children with chronic renal failure received renal replacement therapy
during the adult age, and chronic renal diseases with glomerular
involvement progressed more rapidly than the other chronic renal
diseases.
Calcium carbonate as phosphate binder in hemodialysis patients. H. I.
Byun, and H.C. Kim, Department of Internal Medicine, Keimyung
University, College of Medicine, Taegu, Korea. We evaluated the
effectiveness of calcium carbonate as a phosphate binder in 30 hemo-
dialysis patients. The study was divided into three different periods:
Aluminum hydroxide gel period, followed by no phosphate binder
period and a final calcium carbonate period. Serum phosphate level on
aluminum hydroxide gel was 6.2 1.6 mgfdl, which decreased signifi-
cantly (P < 0.001) to 5.6 mg/dl during calcium carbonate therapy.
Serum levels of total and ionized calcium on aluminum hydroxide gel
was 8.0 1.0 mgldl and 2.30 0.28 mEq/liter, respectively, which
increased significantiy (P < 0.01) to 8.4 1.0 mg/dl and 2.39 0.27
mEg/liter, during calcium carbonate therapy. Calcium x phosphorus
product, serum bicarbonate, alkaline phosphatase, and parathyroid
hormone levels were not significantly different between the groups. The
mean dose of calcium carbonate required to maintain the serum
phosphorus in the normal range was 3.75 0.85 g. There was no
significant difference in serum concentrations of calcium, phosphorus,
alkaline phosphatase and PTH between patients with vitamin D and
those without vitamin D during the calcium carbonate period. There
were five hypercalcemic episodes in three patients in the calcium
carbonate group, compared to two hypercalemic episodes in two
patients in the aluminum hydroxide gel group. Other side effects of
calcium carbonate were minimal except for one episode of diarrhea. We
conclude that calcium carbonate is an effective and safe phosphate
binder in hemodialysis patients and should replace aluminum hydroxide
for this purpose.
Changes of bone metabolism indIces following successful renal trans-
plantation. J.W. Kim, D.S. Bang, J.H. Ahn, T.W. Lee, C.G. Ihm, and
M.J. Kim, Department of Internal Medicine, Kyung Hee University
School of Medicine, Seoul, Korea. Renal osteodystrophy is a common
and troublesome complication of chronic renal failure. Renal transplan-
tation may improve renal osteodystrophy by abolishing the pathophys-
iologic effects of renal failure on mineral metabolism and bone, Immu-
nosuppressive agents such as steroids, however, may induce the
osteoporosis. Therefore, the outcome of renal transplantation on renal
osteodystrophy is interesting. To evaluate the effects of the renal
transplantation on renal osteodystrophy, bone mineral density (BMD)
and total bone calcium (TBC) were measured by dual energy X-ray
absorptiometry and the changes of the biochemical indices of bone
metabolism were evaluated before and after renal transplantation in 12
renal allograft recipients who were immunosuppressed with the medi-
cation of low dose prednisolone, cyclosporin A, and azathioprine. The
results were as follows: (1) After 12 months of renal transplantation,
seven of twelve patients maintained good renal function (SCr c 1.5
mg/dl) and the rest showed mild renal insufficiency. The degree of
elevation of serum calcium and the reduction of serum parathyroid
hormone were more marked in patients with good renal function
compared to those with mild renal insufficiency. (2) The level of serum
phosphorus were significantly reduced after one and twelve months of
renal transplantation, and no patients showed hypophosphatemia. (3)
The level of serum calcium was gradually increased after renal trans-
plantation and the level of calcium at twelve months of renal transplan-
tation was significantly higher than that at pretransplantation and that at
one month after transplantation. Two patients showed mild hypercal-
cemia. (4) After twelve months of renal transplantation, the level of
serum parathyroid hormone became normal in seven patients and the
remainder showed mild hyperparathyroidism. In patients with normal
PTH level, the level of serum ereatinine was significantly lower and that
of serum calcium was significantly higher than those in mild hyperpara-
thyroidism. (5) Bone mineral density (BMD) increased by 0.9% and
0.6% after one and twelve months of renal transplantation, respec-
tively. The total bone calcium (TBC) increased by 0.5% and 0.8% after
one and twelve months of renal transplantation, respectively. However,
this small increase of BMD and TBC was statistically insignificant. In
conclusion, BMD and TBC slightly, but not statistically significantly,
increased with the improvement of renal function and the level of serum
calcium, phosphorus and parathyroid hormone after twelve months in
renal transplanted patients on low-dose steroid immunosuppressive
regimens.
Therapeutic effect of gemfibrozil on hyperllpidemia in patients with
CAPD. S.H. Sohn, S.Y. Rha, 11.5. Kim, 1K. Kim, K. H. Choi, S.K.
Ha, H. Y. Lee, andD.S. Han, Department of Internal Medicine, Yonsei
University, College of Medicine. Hyperlipidemia developing secondary
Abstracts 1457
to CRF is characterized by elevated triglyceride (TO), cholesterol and
reduced high-density lipoprotein cholesterol (HDL-C). It has been
reported that clofibrate has been shown to correct effectively the lipid
abnormality by activation of lipoprotein lipase in CRY patients includ-
ing CAPD patients. However, very few studies have been reported on
the clinical effects of gemfibrozil (Lopid®), which has similar mecha-
nism of action with clofibrate. The effects of gemfibrozil were studied
from March, 1988 to March, 1991 in Severance Hospital, Yonsei
University. Twenty-one CAPD patients with hyperlipidemia, receiving
gemfibrozil daily for more than 12 months, were analyzed. The follow-
ing results were observed: (1) The average age of twenty-one cases was
48.18 11.79 years, and the ratio of male to female was 4:3. (2) The
average serum level of triglyceride was 497.0 465.7 mg/dl before
treatment, 420.5 258.9 mgldl at the 1st month, 345.1 162.5 mgldl at
the 3rd month, 317.4 215.2 mg/dl at the 6th month, and 302.7 221.0
mgldl at the 12th month. The level started to decrease from the 1st
month, and maintained during the follow-up period. In 13 cases (60%)
the serum level fell greater than or equal to 20% on average, compared
to those values before treatment. (3) The average serum level of HDL-C
was 28.0 9.0 mgldl before treatment, 25.7 6.7 mg/dl at the 1st
month, 30.9 11.2 mg/dl at the 3rd month, 23.9 9.0 mgldl at the 6th
month, 33.3 11.7 mgldl at the 12th month, and in 8 cases (38%)
increased greater than or equal to 20% at the 12 month, compared to
those values before treatment. (4) The average serum levels of choles-
terol and LDL were 246.1 65.6 mg/dl, and 200.4 62.3 mg/dl,
respectively, before treatment, and 253.2 58.6 mg/dl and 217.5
59.4, respectively, at the 12th month. (5) The average atherogenic index
(cholesterollHDL) was 9.51 3.61 before treatment, 9.91 3.81 at the
1st month, 8.77 3.03 at the 3rd month, 11.76 9.68 at the 6th month
and 9.74 4.37at the 12th month with no change. The index decreased
greater than or equal to 20% in 8 cases (38%) at the 12th month
compared to those values before treatment. Based on this study,
administration of gemfibrozil in CRF patients with hyperlipidemia
resulted in decreased TO and increased HDL, and, especially, the
serum level of TO started to fall from the 1st month and maintained
during the follow-up period. Therefore, gemfibrozil is thought to be
effective for the treatment of hypertriglycemia in patients with CAPD.
Tryptophan (Tip) metabolism in chronic renal failure (CRF). S.H.
Kim, T.H. Kwon, D.K. Cho, M.K. Kim, J.C. Kim, and T.H. Chung,
Departments of Internal Medicine and Immunology, Kyungpook Na-
tional University, School of Medicine, Taegu, Korea. In contrast to the
widely accepted observation that Trp is decreased in CRF, the patho-
genesis is unknown. Interferon-gamma(IFN- produced by activated T
lymphocytes has recently been known to induce indoleamine-2,3 diox-
ygenase (IDO), the enzyme which accelerates degradation of Trp and
produces kynurenine (Kyn) accordingly. Kyn is known to have neuro-
toxicity in some immunological diseases including HIV infection. To
determine whether decreased Trp in CRF is caused by an accelerated
Trp degradation by IFN-y, we measured serum levels of Tip, Kyn and
neopterin (which reflects the activity of IFN-y indirectly) in 28 CRF
patients (19 hemodialysis patients, 9 CAPD patients), 13 stable renal
transplants, and 28 normal controls. The Tip level was significantly
lower (P < 0.01) in the CRF patients (5.95 1.24 g/m1) than both the
normal controls (13.08 2.40 gIml) and the renal transplants (12.17
1.66 sgIml). Kyn was significantly higher (P < 0.01) in the CRF patients
(0.80 0.20 g/ml) than both the normal controls (0,49 0.15 g/ml)
and the transplants (0.52 0.04 gIml). Neopterin was significantly
higher (P < 0.01) in the CRF patients (342.9 205.9 nmol/liter) than
both the normal controls (5.0 2.2 nmollliter) and the transplants (16.3
4.6 nmollliter). These data indicate that decreased Tip level in CRF
is associated with degradation of Tip through the induction of IDO by
IFN-y. Clinical significance of increased Kyn in uremic neuropathy
deserves further study.
Plasma potassium concentration and influence of beta adrenergic
blockade (Carteolol) or ACE inhibitor (Captopril) on maintenance hemo-
dialysis. W.M. Kim, C.O. Moon, and H.J. Kim, Department of Internal
Medicine, College of Medicine, Chosun University, Kwangju, Korea.
The prevalence of hyperkalemia, effect of potassium removal by
hemodialsis on the plasma potassium concentration to see the kinetic
analysis of the distribution of potassium, and influence of beta adren-
ergic blockade and ACE inhibitor on them were done by 28 studies on
16 patients (9 patients on carteolol or captopril) with end-stage renal
disease undergoing maintenance hemodialsis. The following were ob-
served: (1) The mean predialysis plasma potassium concentration of all
28 studies, group 1 on medication (17 studies), and group 2 (11 studies)
without medication was 5.13 1.04, 5.67 1.01 and 4.41 0.55, with
high significance (P < 0.001) between groups 1 and 2. (2) The absolute
fall in plasma potassium during hemodialysis was significantly corre-
lated with the predialysis plasma potassium (r = 0.9, P < 0.001).
However, there was a significant negative correlation between the ratio
of end to predialysis potassium concentration (r =
—0.73, P < 0.001)
rather than constant fractional changes during dialysis. (3) The pre- and
end-dialysis concentration of plasma sodium, glucose, pH and bicar-
bonate between group 1 and group 2 was similar except glucose. (4)
There was no correlation between changes of plasma potassium con-
centration during dialysis and dialysis potassium clearance rate mea-
sured at 1 hour of hemodialysis. Also, despite the fall in absolute plasma
potassium concentration in group 1 was more than twice than that in
group 2, the difference in dialysis potassium clearance rate in group I
compared to that of group 2 was only 12%. These data are consistent
with at least a two-compartment distribution of plasma potassium rather
than single pool in addition to frequent hyperkalemia on maintenance
hemodialysis on beta adrenergic blocker or ACE inhibitor contributed
to partial impairment of extrarenal transcellular shifts of potassium
during inter- and intra-dialytic phase.
Effect of long-term captopril, indomethacin and verapanül in chronic
uremic rats. S. Y. Kim, Y.S. Kim, W.S. Koo, V.5. Chang, Y.S. Yoon,
and BK. Bang, Department of Internal Medicine, Catholic University
Medical College, Seoul, Korea. The objectives of this study were to
evaluate the effects of long-term Captopril, indomethacin and verapamil
treatment on the outcome of the remnant kidney model of chronic renal
failure in rats. The staged subtotal nephrectomy was established in male
Wistar rats subjected to segmental infarction of two-thirds of the left
kidney and surgical removal of right kidney. Four weeks were allowed
for remnant kidney hypertrophy before determining the response to
renal ablation of individual animals regarding proteinuria and hyperten-
sion. The rats were divided into 5 groups. Group I had 7 uremic rats
served as controls. Group 2 had 7 uremic rats treated with Captopril.
Group 3 had 7 uremic rats that received indomethacin. Group 4 had 7
uremic rats treated with captopril and indomethacin. Group S had 7
uremic rats that treated with verapamil. Treatment was continued for 4
months. The results were obtained as follows: (1) Serum creatinine was
similar in group 2, 3, 4 and 5 compared to untreated group 1 during
whole experimental period. (2) Blood pressure (mm Hg) was lowered by
Captopril and verapamil treatment. Two months post-treatment, sys-
tolic blood pressure in the untreated group 1 was 182 8, group 2 144
4 (P < 0.05), group 4 149 5 (P < 0.05), and group 5 138 5 (P <
0.05). The blood pressure lowering effect of Captopril was observed at
three months post-treatment. However, verapamil barely lowered
blood pressure despite the high dose at this time. Systolic blood
pressure in group I was 173 8, group 2 143 3 (P <0.05), group 4 136
4 (P < 0.05), and group 5 150 4. (3) Proteinuria (mg124 hr) was
decreased by captopril and indomethacin treatment, but not verapamil
administration. Four months post-treatment, proteinuria in the un-
treated group 1 was 159 26.8, group 2 80.0 9.5 (P < 0.05). Group
3 60.3 8.2 (P < 0.05), group 4 54.1 1.1 (P < 0.05), and group 5 was
181.9 50.4. (4) Glomerulosclerosis (% of glomeruli with segmental or
global sclerosis) was reduced with Captopril treatment but not indo-
methacin or verapamil treatment. Four months post-treatment, glomer-
ulosclerosis in the untreated group 1 was 24.5 4.8, group 2 9.4 2.9
(P <0.05), group 3 12.5 3.2, group 4 13.0 2.8, and groups was 15.3
2.4. In summary, these results suggest that angiotensin converting
enzyme inhibitor, Captopril, effectively controls systemic hypertension
and proteinuria and limits glomerular injury in rats with reduced renal
mass. Also chronic indomethacin administration significantly amelio-
rated the development of progressive proteinuria. In contrast, vera-
pamil treatment failed to alter the natural course of rats subjected to
subtotal nephrectomy.
Clinical trial of recombinant human erythropoletin (rHuEPO) for
anemia of end-stage renal disease. S.J. Park, M.S. Kim, M.I. Park, S.H.
Yang, S.E. Park, and S.R. Lee, Department of Internal Medicine,
Kosin Medical College, Pusan, Korea. Although the mechanisms
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underlying the anemia of end-stage renal disease (ESRD) are complex,
a reduced EPO production can be one causative factor. The current
treatment for anemia of ESRD includes anabolic steroids and red blood
cell transfusions. The adverse effects of anabolic steroid therapy,
virilization and elevation of SGOT and SGPT, may be significant.
Multiple transfusion therapy is associated with many iatrogenic prob-
lems, including the iron overload, the risk of blood-borne viral infec-
tion, the development of HLA antibodies, and suppression of bone
marrow. We administered rHuEPO 50 lU/kg thrice weekly to 21 anemic
patients with ESRD who were undergoing hemodialysis (13), CAPD (3),
kidney transplantation (I), and conservative therapy (4), at Kosin
Medical College from December 1990 to April 1991. The patient mean
age was 43.4 years and M/F ratio was 1.6:1. Hemoglobin, hematocrit,
number of RBC after 1, 2, 3 months of treatment were increased with
statistical significance. Serum iron, TIBC were decreased with statisti-
cal significance, and serum ferritin was decreased without significance.
Serum phosphorus was increased, and serum K, BUN, creatinine,
chest x-ray, cardiothoracic ratio and ECG after treatment revealed no
significant change. Systolic BP after treatment was significantly in-
creased, and diastolic BP increased without significance. There was an
increase of 1 g% of Hgb after 2.7 weeks of treatment with EPO 22,800
IU. And it took 5.27 weeks of treatment with EPO 47,100 IU for
patients to have 2 g% increase. They required transfusions of 0.9
pint/month before the therapy, however, they did not require any
transfusion after the treatment. Side effects of EPO were aggravated
hypertension (1), elevated SGOT/SGPT (1), itching (4), and allergic
reaction (1). Improvements of sleep pattern (4), appetite (8), and
activities were noted.
Pretreatment 2 months 3 months
Hemoglobin 6.70 0.93 8.33 1.OOa 9.63 0.59°
g/dl
Hematocrit % 20.34 2.97 25.38 3.30° 30.01 1.82°
RBC IO mm3 224.57 37.44 279,16 13.79a 314.33 23.87°
Iron pg/dl 133,26 43.40 93.60 30.72 75.28 21.73
TIBC sg/dl 238.11 44.97 191.70 42.84° 161.42 30.78a
Ferritin ng/dl 1386.71 643.00 1123.56 707.40 1163.21 48.48
P mg/dl 6.02 1.08 6.40 1.25 7.22 0.86
Systolic BP 140.48 16.27 156.36 22.03° 156.25 9.16a
mm Hg
Diastolic BP 87.52 13.96 98.18 14.01 101.25 8.34
mm Hg
Data are presented as mean
pretreatment
standard deviation, a p < 0.05 vs.
These results demonstrate that rHuEPO is effective and safe with the
increase of hematocrit in many patients with anemia of end-stage renal
disease.
Effects of human erythropoietin therapy In hemodialysis patients. S.G.
Lee, S.H. Sohn, S.B. Park, and H.C. Kim, Department of internal
Medicine, Keimyung University, School of Medicine, Taegu, Korea.
Twenty-one patients with end-stage renal disease and anemia who were
on maintenance hemodialysis were treated with human erythropoietin
(rHuEPO). The 50 U/kg of rHuEPO was given intravenously three
times weekly after dialysis, and transfusion requirements, hemoglobin,
hematocrit, ferrokinetics, and reticulocyte responses were monitored.
The mean hemoglobin concentration rose significantly from pretreat-
ment level of 5.8 1.2 g to 7.1 1.7 g at 4 weeks, 9.1 1.5 g at 8
weeks, and 9.9 1.5 g at 12 weeks (P < 0.001). Mean reticulocyte
count increased from pretreatment level of 1,7 1.1% to 2.2 1.0% at
8 weeks after treatment, without statistical significance. The mean
transfusion requirement in the 3 months preceding therapy with
rHuEPO amounted to 2.2 pints but none of the patients needed further
transfusion during rHuEPO therapy. Serum iron concentrations were
131 59 tg/ml in the baseline state and 104 62 g/dl at 8 weeks after
treatment. Total iron binding capacity was 258 65 g/d1 in the
baseline state and 260 46 g/dl 8 weeks after treatment. These values
are not statistically different. In contrast, serum ferritin concentration
decreased significantly from 2389 3611 ng/ml before treatment to 1367
1737 ng/ml (P < 0.05) 8 weeks after treatment. There were no
significant changes in laboratory parameters including BUN, serum
creatinine, potassium, phosphate, and body weight during rHuEPO
therapy. Although antihypertensive therapy was increased in two
patients, the mean arterial pressure did not change significantly during
rHuEPO therapy. Adverse effects resulting from rHuEPO treatment
were minor except for a flu-like illness. It is concluded that rHuEPO is
very effective in treating the anemia of patients who are maintained on
hemodialysis.
Effects of human recombinant erythropoletin (rHuEPO) on cell-medi-
ated inununity in hemodlalysis (lID) patients. Y.S. Lee, S.H. Sohn, Y.K.
Kim, K.H. Choi, H. Y. Lee, and D.S. Han, Department of Internal
Medicine, Yonsei University, College of Medicine, Seoul, Korea. To
evaluate the possible effects of rHuEPO on the immune system, we
studied peripheral blood lymphocyte subpopulations (total lympho-
cytes, B- and T-lymphocytes, T-cell subsets) and mitogenic response to
PHA (phyrohemagglutinin) and ConA (Concanavalin A), and NK
(natural killer) cell activity before and after 3 months in 10 HD patients
who were on rHuEPO. After rHuEPO therapy, hemoglobin was mark-
edly increased to 6.21 0.55 g/dl, compared to the pretreatment value
10.19 0.73 g/dl (P < 0.05). Although there was no significant
difference in the absolute numbers of lymphocytes, total T- and B-cells,
the proportion of helper (OK T4) T-cells were significantly reduced
(43.2 4.8% vs. 36.7 11.1, P <0.05). However, stimulation indices
to PHA or ConcA was not markedly reduced, whereas NK cell
activities were highly increased, compared to the pretreatment values
(46 12% vs. 60 15, P < 0.05). Based on these results, the rise in
hemoglobin with rHuEPO treatment seems to be accompanied by
enhancement of NK cell activities and reduction of the proportion of
helper T-cells without decrease of lymphocyte mitogenic response.
Effects of erythropoietin-lnduced hemopolesis on peritoneal transport
and in vitro T-cell responses in CAPD. S.K. Lee, D.C. Han, M.S. Park,
S.D. Hwang, C. Moon, and H.B. Lee. Hyonam Kidney Laboratory,
Soon Chun Hyang University, Seoul, Korea. To investigate the thera-
peutic efficacy of subcutaneously administered erythropoietin (EPO)
and the effects of EPO-induced hemopoiesis on peritoneal transport and
on cellular immune responses, we performed peritoneal equilibration
tests as described previously and measured T-cell subsets and PHA-
induced interleukin 2 receptor (IL-2R) expression of PBMC by flow
cytometry before and after subcutaneous EPO (EprexR, Cilag), 4000 U
twice weekly, in 13 CAPD patients (6 M and 7 F, age 39.4 14.8 years,
CAPD duration 27.9 28.7 months). Hct increased from 21.3 3.4%
to 30.0 4.8%after 1 month and to 32.7 4.9%after 2 months of EPO.
Drained volume after 4 hours of dwell with 4.25% dialysate increased
from 2,675 204 ml to 2,807 174 ml (P < 0.05). D4/P4 creatinine
increased from 0.68 0.07 to 0.71 0.06 (P < 0.05) and creatinine
clearance from 7.57 0.71 to 8.03 0.63 mI/mm (P < 0.05). The
number of total circulating lymphocytes, T4, T8, T4/T8 with and
without PHA did not change after EPO. PHA-induced IL-2R expres-
sion by PBMC as expressed by mean channel fluorescence intensity
increased from 149.8 6.7 to 156.8 6.1 (P < 0.05). In conclusion,
subcutaneous EPO is effective in correcting anemia in CAPD patients.
EPO-induced hemopoiesis is associated with increase in peritoneal
creatinine and water transport and also with increased PHA-induced
IL-2R expression.
Effect of rHuEPO on muscle energy metabolism In patients with
end-stage renal disease using 31P-NMR spectroscopy. J.S. Park, S.K.
Park, S.B. Kim, T.H. Lim, 1'. Yi, D.K. Lee, and C.D. Hong, Depart-
ments of internal Medicine and Radiology, UI San University, School
of Medicine, Asan Life Science Institute, Seoul, Korea. Although the
patients with end-stage renal disease (ESRD) frequently complain of
muscle fatigue and general weakness, the mechanism of those symp-
toms has not been elucidated. rHuEPO, which has been used recently
for treatment of anemia in the patients with ESRD, has been known to
improve exercise capacity and muscle weakness as well as function of
various organs. 31P-NMR spectroscopy is one of the effective and
non-invasive methods to measure change of energy metabolism in vivo.
To evaluate the effect of rHuEPO on muscle energy metabolism in
patients with ESRD, we measured intracellular pH, phosphocreatin
(Per) and inorganic phosphate (Pi) before and after all-out exercise" at
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pretreatment, 4 weeks and 8 weeks after start of rHuEPO treatment in
10 patients on maintenance hemodialysis who received 3,000 U of
rHuEPO (EpoginR) three times a week. The results were as follows:
Resting state
Baseline 4 weeks 8 weeks
Hematocrit 18 2.6 22 2.1 29 3.5
pH
Pcr/Pi
6.99 0.22
6.13 1.l2I
6.99 0.23 6.99 0.02
7.91 l.46a 8.67 2.07"
Baseline
Maximum recovery states
4 weeks 8 weeks
Hematocrit 18 2.6 22 2.1 29 3.5
pH
PcrIPi
6.98 0.37
8.92 1.42a
6.98 0.42 6.98 0.06
11.22 2.73" 8.67 207a,b
P < 0.05, One way ANOVA, Fisher test
a Difference between Baseline and 8 weeks
b Difference between 4 weeks and 8 weeks
These results showed rHuEPO improved the energy reservoir in the
resting state, irrespective of duration of rHuEPO treatment and hema-
tocrit. The maximum energy reservoir during recovery after exercise
increased with duration of rHuEPO treatment.
The effects of intraperitoneal verapamil on j32-nücroglobulin in patients
with diabetic renal failure during CAPD. N.J. Byun, D.R. Cha, H.M.
Kwon, Y,J. Kwon, W. Y. Cho, and H.K. Kim, Department of Internal
Medicine, Koresa University Hospital, Seoul, Korea. To evaluate the
effects of calcium antagonist (verapamil) on the permeability of the
peritoneal membrane in patients on CAPD, serum levels and clearances
of creatinine, urea and /32-microglobulin, mass transfer-area coeffi-
ciency (MTAC), ultrafiltration rate and glucose absorption were mea-
sured. The study group was divided by 5 non-diabetic (age 33.4 12.4
years, treated for 10.1 8.4 months, Group I) and 5 diabetic (age 53.2
13.7 years, treated for 16.6 15.2 months, Group II) renal failure
patients and the study was carried out using 1.5% dextrose dialysate
solution for 240 minutes of dwell time (phase I). After the intraperito-
neal administration of 10 mg of verapamil the peritoneal dialysis was
done by the same method as phase I (Phase II). To evaluate the effects
of verapamil, percent differences of change between phase I and phase
II were calculated. All the values are mean SD. The results were: (1)
Serum levels of creatinine and 132-microglobulin were lower in group II
(6.8 vs. 11.4 mgldl, 18.2 vs. 39,4 mg/i; P < 0.01). (2) Peritoneal
clearance of creatinine was higher in Group 11(7.072 vs. 6.322 mI/mm),
but the increasing rate after instillation of verapamil was slightly lesser
than Group I (4.0 vs. 6.5; not significant). (3) Peritoneal clearance of
i3-microglobulin was higher in Group 11(0.88 vs. 0.63 mI/mm), and the
increasing rate after instillation of verapamil was marked in both
groups, especially in Group 11(36.1 vs. 83.5%; not significant). (4)
MTAC was higher in Group 11(12.78 vs. 9.7 mI/mm), but the increasing
rate of it was greater in Group 1(3.58 vs. 15.4%; not significant). The
peritoneal permeability was greater in Group II, probably due to
increased permeability and changed structures of peritoneal capillaries
in diabetic disease. The effect of calcium antagonist (verapamil) on
peritoneal permeability was less in Group II, suggesting that intraperi-
toneal administration of verapamil increases the efficiency of CAPD in
general, but the benefit may be less in diabetic patients.
Follow-up peritoneal clearances in diabetics. M.S. Park, D.C. Han,
S.K. Lee, S.D. Hwang, C. Moon, and H.B. Lee. Hyonam Kidney
Laboratory, Soon Chun Hyang University, Seoul, Korea. We per-
formed follow-up peritoneal clearance studies in eight diabetic CAPD
patients to evaluate the stability of peritoneal membrane function over
time. Seven of these 8 patients were constituents of 13 diabetics in
whom the baseline clearances were previously reported (Pent Dial mt
10:85—88, 1990). Six patients had discontinued CAPD and were not
available for follow-up studies. The baseline clearance studies were
obtained in 46.0 45.4 days and follow-up clearances 27.9 6.0
months after beginning CAPD. Clearances of urea (Cura) and creatinine
(Ccr) and drained dialysate volume were unchanged at the follow-up
when compared to the baseline values both before and after nitroprus-
side. Clearance of protein (Cprot) was significantly lower at the fol-
low-up when compared to the baseline values both before and after
nitroprusside. Nitroprusside caused a significant increase in Cura, Ccr
and Cprot at both baseline and follow-up periods. In conclusion,
peritoneal clearances of urea and creatinine, drained volume and the
responsiveness of peritoneal microcirculature to nitroprusside were
well maintained for up to 2 years after CAPD was begun in diabetics.
Clearance of protein, however, decreased in the follow-up periods.
Serum cholesterol change and its risk factor analysis on hypercholes-
terolemia during continuous ambulatory peritoneal dialysis. H.S. Kim,
S.H. Sohn, H.S. Shin, Y.K. Kim, K.H. Choi, H. 1'. Lee, andD.S. Han,
Department of Internal Medicine, Yonsei University, College of Med-
icine, Korea. Hypercholesterolemia and hypertriglyceridemia was al-
ready reported in continuous ambulatory peritoneal dialysis (CAPD)
patients, but in some patients no definite change was noted. So we
thought that there would be some risk factors affecting the hyperlipid-
emia. We studied 102 patients among 274 patients who were treated
with CAPD for more than 12 months in Severance hospital, Yonsei
University on March 1991. Diabetes mellitus, which disease itself can
affect the lipid metabolism or the patients who were treated with drugs
which can affect the lipid metabolism were excluded. Three groups
were made according to the cholesterol change before and after 12
months of CAPD; no change group (increment of serum cholesterol <
0 mg/dI), minimal increase group (0 increment of serum cholesterol <
50 mg/dl), moderate increase group (increment of cholesterol  50
mgldl). Each group was named group I (N = 27), II (N = 45), III (N =
30). Sex ratio of each group was 1:0.8, 1:0.96, 1:2.3, and the mean age
was 42.9 12.7, 42.7 14.2, 44.8 10.2 years, which revealed female
predominance in group III. No statistical difference on the mean age
among the three groups. Serum cholesterol before CAPD was in group
1194.9 37.6 mg/dl, group 11170.1 35.5 mg/dl, group III 144.2 33.5
mg/dl; group III was the lowest (P < 0.05). There was significant
increase in serum cholesterol in groups II and III after 1 month; after 12
months it reached 190.0 35.0 mg/dl, 230.3 35.7 mg/dl, which was
statistically significant. Serum triglyceride increased significantly after I
month and throughout the study period in group II, and change in serum
HDL-cholesterol did not reach statistical significance. The increment of
serum cholesterol after 12 months of CAPD and seven risk factors (sex,
age, serum total protein, serum albumin, serum BUN/Cr ratio, inci-
dence of peritonitis, ideal body weight change before and after 12
months of CAPD) were analyzed by multiple regression method in 102
patients. Sex was the only statistically significant risk factor due to the
increase of cholesterol in patients who were on 12 months of CAPD
(significant T = 0.016). Increment of cholesterol before and after 12
months of CAPD among the 102 patients was negatively correlated
(correlation coefficient r =
—0.55, P < 0.001) which means that the
lower the cholesterol at the start of CAPD, the higher the increase of
cholesterol after 12 months of CAPD. In conclusion, the increase of
serum cholesterol was not revealed in all patients; cholesterol was more
significantly increased in females than males in cases of lower serum
cholesterol level before the CAPD. A special interest in diet control on
female patients is needed, even if they have lower serum cholesterol
levels before CAPD. More study involving variable risk factors is
needed.
Effects of subcutaneously implanted catheters on the incidence of
peritonitis during CAPD. D.C. Han, H.K. Cha, S.H. Chung, M.S.
Park, S.K. Lee, S.D. Hwang, C. Moon, and H.B. Lee, Hyonam Kidney
Laboratory, Soon Chun Hyang University, Seoul, Korea. Recent
experiences with Y-connector suggest that flush-before-fill effectively
reduces transluminal infection. Periluminal route of infection, however,
remalns a problem. We examined the effects of a new peritoneal access
technique, as described by Moncrief, and the incidence of peritonitis in
CAPD patients. In this technique the external segment of pentoneal
catheter remains implanted subcutaneously for 6 weeks before exteri-
orization. This allows healing and tissue ingrowth into the Dacron cuff
in a sterile environment. During a period of 6 months between 9/26/90
and 3/31/91, peritonitis developed once every 10.7, 10.5, 16.1 and 50.1
patient-months (pm) in conventional straight connector (S:Duration of
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observation 202.5 pm), conventional Y-connector (Y:483.3 pm), im-
planted S (48.3 pm) and implanted Y (50.1 pm), respectively. Cumula-
tive probability of experiencing the first episode of peritonitis at 3
months were 52.1, 36.7 and 13,5% in conventional S, conventional Y
and implanted S and Y combined, respectively. In conclusion, the
preliminary experience with the subcutaneously implanted peritoneal
catheter suggests that peritonitis incidence can be further reduced by
eliminating periluminal route of infection (and biofllm formation) in
CAPD patients.
The graft survival rates and stability of renal allograft function
associated with cyclosporine immunosuppressive therapy. KR. Sung,
K.W. Khang, C.H. Park, ftC. Park, and G.M. Kang, Department of
Internal Medicine, College of Medicine, Hanyang University, Seoul,
Korea. We have performed 149 renal transplantations in Hanyang
University Hospital since April 1978. We have analyzed the graft
survival rates and stability of renal allograft function of 126 patients that
have been followed up according to donor types, immunological factors
and immunosuppressants. We also analyzed complications of cyclo-
sporine immunosuppressive regimen and effects of H2-receptor antag-
onists on allograft function in CsA-treated renal transplant patients. The
results are as follows: (1) The mean age of rccipients was 34.3 years,
and the male to female ratio was 5:1. They were primarily in their fifties
and sixties. Among 149 patients, 121 patients received kidneys from
living related donors and 13 patients were cadaver transplantations. Of
living related donors, mothers donated in 55 cases. (2) The rate of
infectious complications of renal transplantation between azathioprine
(Aza) and cyclosporine (CsA) immunosuppressive regimen groups had
no difference. Among non-infectious complications, the graft rejection
rates were higher in the Aza group and hepatotoxicity was common in
the CsA group. Hepatic failure occurred only in the Aza group. (3) The
graft survival rates were the highest in sibling donors, and the graft
survival rates of cadaver donors had no difference in those of living
unrelated donors, (4) The major causes of patient deaths before 1982
were infection and acute graft rejection, but those after 1983 were due
to hepatic failure and pneumonia. In 3 cases, the causes of death were
uncertain, (5) The graft survival rates of CsA immunosuppressive
regimen group were superior to those of the Aza group but it was not
statistically significant. The most common cause of graft loss was
chronic rejection in both groups. (6) In immunologic factor, HLA-ABC
antigen, donor specific transfusion (DST) and relative response of
mixed lymphoeytic culture (MLC) had no influence on graft survival
rates, but HLA-DR antigen, HBs-Ag and the number of transplanta-
tions influenced graft survival rates. (7) GsA was associated with
impaired but generally stable allograft function, The aggregate rate of
decline of allograft function in CsA immunosuppressive regimen group
did not differ from that of the Aza group. Progressive loss of function in
the CsA group appeared to reflect the effects of chronic immunologic
injury rather than primary nephropathy caused by GsA therapy. We
could not exclude the possibility of CsA nephropathy because we found
a fall of serum creatinine level in some eases by change of immunosup-
pressants from CsA to Aza. (8) The observed elevation of serum
creatinine concentration during H2-receptor blocker therapy in GsA-
treated renal transplant patients could be explained by Hrreceptor
blocker competing with creatinine for tubular secretion. Serum creati-
nine levels in most cases returned to baseline values in one month of
H2-receptor blocker termination, but they were not statistically signif-
icant.
Twenty-two years of renal transplantation at Catholic Medical Cen-
ter—experience of 600 transplants. Y.S. Yoon, V.5. Kim, B.K. Bang,
Y.-H. Park, G.J. Park, and Y.B. Koh, Department of Internal Medi-
cine, Department of Urology, Department of Anesthesia, Department
of General Surgery, Catholic University Medical Center, Seoul, Korea.
The results of twenty-two years of renal transplantation at the Catholic
Medical Center have been reviewed to analyze data of transplants
performed between March 1969 and March 1991. During this time our
center has transplanted 578 patients with 600 allografts. The data have
been stratified to reflect differences in: (1) donor sources; (2) immuno-
suppressants; (3) diabetics; (4) HBV status; (5) graft number; and (6)
HLA matching. Overall actuarial 5-year patient and graft survival were
77% and 66%, respectively, with 66% graft survival for LRD, 70% for
NRD and 44% for CAD. The actuarial graft survival rates at 5-year were
51% in the Aza group, and 76% in the GsA group (P = 0.00001). Overall
5-year graft survival for diabetics was 62% versus 66% for nondiabetics.
Overall 5-year graft survival for HBV positive group was 61% versus
78% for HBV negative group. Overall 5-year graft survivals for HLA-
identical, haploidéntical, and mismatches were 75%, 54% and 31% in
the Aza group (P C 0.05); and 77%, 77% and 81% in the CsA group. In
conclusion, the best graft survival rates were obtained in recipients who
received CsA for immunosuppression and HLA-identical, but not in
donor sources, (diabetics or not), HBV status, or graft number.
Diffuse interstitial pneumonia in GsA-treated renal transplant recipi-
ents. C.W. Park, Y.S. Kim, V.5. Yoon, B.K. Bang, K.Y. Lee, andK.H,
Yang, Department of Internal Medicine, Department of Clinical Pa-
thology, Catholic University, Medical College, Seoul, Korea. Diffuse
interstitial peumonia (DIP) is a variety of serious diseases occurring in
renal transplants. To assess the incidence, associated clinical features,
precipitating factors, morbidity and mortality, we retrospectively re-
viewed the records of patients undergoing renal transplantation at CMC
from May I, 1984 through Feb 30, 1991. A total of 431 transplants were
performed during this period. DIP was diagnosed in 25 patients (mean
age: 39 years) for an overall incidence of 5.8%. The male:female ratio
was 16:9. Of the 25 patients, 19 patients received a NRD and the others
LRD. DIP occurred within 3 months post-transplant in 21/25 patients
with average onset 3 months (range 2—41). When compared with
non-infected recipients, there was no significant difference with regard
to sex, donor source, and serum creatinine level. However, diabetics
were highly associated with the development of DIP (P C 0.05).
Rejection episodes occurred in 7/25 patients (28%). Blood GsA level
elevated above recommended therapeutic window level, Fever and
hypoxia were the most common presenting symptom and sign. Defini-
tive diagnoses were achieved in 11/25 (44%) of patients: Cytomegalo-
virus (CMV) identified in six, aspergillus in two, candida albicans in
two, and M. tuberculosis in one. Sixteen patients recovered, and 9 died
for a mortality rate of 36%. In conclusion, (1) DIP is a serious
pulmonary problem with a high morbidity and mortality in GsA-treated
renal transplant recipients. (2) The majority of cases occur within the
first 3 months post-transplant. (3) It occurs more frequently in diabetics
and in the setting of increased immunosuppression. (4) The etiologic
agents were CMV infection in 6 patients, aspergillus in 2 patients,
candida albicans in 2 patients. M. tuberculosis in one patient, and
unknown in 14 patients. (5) As a result of this review, we recommend
that early diagnosis and specific treatment should be done for successful
management.
Infection following renal transplantation. H.G. Kim, S.B. Park, C.H.
Park, and W.H. Cho, Keimyung University Dongsan Medical Center,
Taegu, Korea. Between November 1982 and December 1990, 163 renal
transplantations were performed at Keimyung University Hospital, and
107 episodes of infection were documented. Of these 107 episodes, 55
(51.4%) were caused by bacterial agents, 39(36.5%) by virus, 10 (9.4%)
by fungus, and 3 (2.7%) were due to protozoa. The most common sites
of infection were the skin and mucocutaneous (42%), urinary tract
(18%), the respiratory tract (15%) and wounds (4%), The most impor-
tant viral illness was Varicella zoster virus infection (54%), cytomega-
lovirus disease (25.6%), acute viral syndrome (10.4%), hepatitis B
infection (7.7%) and non-A non-B hepatitis (2.5%). Of 55 episodes of
bacterial infection, four (7.2%), developed bacteremia, and one (25%)
of these infections was fatal. Among non-bacteremic infections, those
of the urinary tract, skin and soft tissue (cellulitis), and pulmonary were
most common. The most frequent causative organisms of urinary tract
infections were Pseudomonas, Enterobacter, E. coli, Staph. aureus and
epidermidis, and gram negative organisms, accounting for 58% of
urinary tract infections. Urinary tract infections were rarely the cause
of bactcremia. Pneumonia occurred in 8(4.9%) patients. Six out of eight
patients had a prior history of steroid pulse therapy, and three patients
with hypoxemia expired at the time of admission. There was no
characteristic pattern of timing of infection after transplantation, except
four of five patients with tuberculosis became ill 5 months after renal
transplantation.
Allograft kidney diseases confirmed by biopsy. C.S. Lim, fT. Cho,
K. U. Chu, S. Kim, J.S. Lee, H.S. Lee, and V.1. Kim, Department of
Internal Medicine and Department of Pathology, College of Medicine,
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Seoul National University, Seoul, Korea. The etiologies of functional
deterioration in allograft kidneys are diverse, and several diagnostic
methods are used for the differential diagnosis. To find out the causes of
allograft kidney diseases, we reviewed the 53 allograft kidney biopsies
in 44 patients admitted to Seoul National University Hospital (SNUH)
from January 1979 to December 1990, and analyzed their clinical
characteristics. During the same period, 274 cases of kidney transplan-
tation were done in SNUH; the ratio of male to female was 4.3:1, and
the age at transplantation was 31.3 10.2 (mean SD) years.
Immunosuppression was done mainly with prednisolone and azathio-
prine until 1983 and thereafter, prednisolone and cyclosporin A were
used in most patients for immunosuppression. The 1 year survival rate
was 91.4% and the number of patients that were followed up and have
functioning allograft kidneys until now is 191 (69.7%). (1) The ratio of
male to female in 44 patients was 5.3:1, and their average age at biopsy
was 31.7 years (range: 9—56 years). (2) In 53 cases of allograft kidney
biopsies, the clinical evidence of functional derangement of allograft
kidneys appeared at 8.9 months after transplantation on average, and
the biopsies were performed at 15.5 months after transplantation on
average. (3) The biopsies were done because of delayed functional
recovery after transplantation in 6 cases, rapid deterioration of renal
function in 17 cases, slow progression of azotemia in 20 cases, persist-
ent proteinuria over 2 glday in 8 cases, and gross hematuria combined
with proteinuria in 2 cases. (4) The results of biopsies were hyperacute
rejection in 1 case, acute rejection in 13 cases, chronic rejection in 14
cases, acute tubular necrosis (ATN) in 4 cases, renal infarct in 3 cases,
tubulointerstitial nephritis in 2 cases, glomerulonephritis in 12 cases,
transplant glomerulopathy in 1 case, CsA nephrotoxicity in 2 cases and
no pathologic lesion in I case. The results of biopsies were rejection,
ATN and renal infarct in 35 cases among the 43 cases in which the major
indication for biopsy was azotemia. And all of the 10 cases in which the
major indication for biopsy was persistent proteinuria and/or hematuria
were glomerulonephritis. (5) The glomerulonephritis in allograft kid-
neys, that is, recurrent or de novo glomerulonephritis, was found in 11
patients (the biopsy was performed twice in one patient), and the
indications for biopsy in these patients were persistent proteinuria in 7
cases, gross hematuria combined with proteinuria in 2 cases and slow
progression of azotemia in 3 cases. The results showed membranous
nephropathy in 3 patients, focal segmental glomerulosclerosis (FSGS)
in 3 patients, membranoproliferative glomerulonephritis (MPGN) type 1
in 2 patients, IgA nephropathy in 2 patients, and minimal change lesion
in 1 patient. In these patients, the clinical evidences of glomerulone-
phritis appeared at 11.4 months after transplantation on average, and
the biopsies were done at 22.4 months after transplantation on average.
In these patients, 2 patients (1 MPGN type 1 patient and 1 FSGS
patient) expired and another 2 patients (1 MPGN type 1 patient and 1
FSGS patient) lost allograft kidney function; the rest of the patients are
maintaining their allograft kidney function. Transplant glomerulopathy
was found in 1 patient. In this patient, the proteinuria was first detected
at 14 months after transplantation and the biopsy was performed at 38
months after transplantation. At present (74 months after transplanta-
tion), this patient has good renal function in spite of persistent protein-
uria. (6) There were no major complications of the biopsies leading to
deterioration of allograft kidney function in these 53 cases, except
bleeding in one case that required transfusion. In conclusion, we found
that various diseases could occur in allograft kidneys and the clinical
manifestations could be similar in different diseases. Although the
probability of glomerulonephritis was high in patients who showed
proteinuria and/or hematuria without azotemia, the possibility of
chronic rejection could not be excluded. Furthermore, if azotemia
occurred together with proteinuria and/or hematuria in allograft kid-
neys, the underlying diseases would be more diverse. Finally, we found
that biopsy was a useful and safe method for differential diagnosis of
allograft kidney diseases.
Ilyperuricemia and associated factors in renal transplanted patients.
K.B. Cho, M.C. Kim, J.S. Choi, S.H. Yang, S.E. Park, and S.R. Lee,
Department of Internal Medicine, Kosin Medical College, Pusan,
Korea. Among 235 kidney transplantation cases performed by Kosin
Medical College Kidney Transplantation Team during 1984 through
December 1990, we reviewed serum creatinine and uric acid levels and
24 hour urine creatinine and uric acid excretions in 132 cases whose
serum creatinine levels had been less than 2 mgldl for at least 3 months
and who had not been taking diuretics. Creatinine clearance (Cj, urate
clearance (Curate), urinary urate excretion (Uurate V) and fractional urate
excretion (FEurate), were calculated. The patients' mean age was 35.7
years and 25 cases were treated with azathioprine (Aza group) and 106
cases with cyclosporin-A (CsA group). Asymptomatic hyperuricemia(serum rate > 7mg/dl) developed in 12.0% of Aza group, 60.4% of CsA
group and 11.1% of 17 controls. Gouty arthritis occurred in 4 cases
treated with CsA.
Control
group CsA group Aza group
No. of cases 17 68 16
BUN mg/dl 12.6 2.6 22.2 61a,b 19.3 34C
Crmg/dl
Su,te mg/dl
Ccr mI/mm
1.0 0.0
4.4 1.4
58.8 21.6
1.3 03a,b
7.2 17a,b
50.2 200k'
1.2 0.2c
5.7 1.7c
61.4 14.1
Cute mi/mm 7.3 4.3 7.2 4.4 7.0 4.6
Uurate V mg/mm 0.30 0.16 0.49 0.29 0.36 0.19
FEurate % 13.9 8.7 14.0 1.5 11.4 6.6
Mean sn
a P < 0.05 vs. Control group
b P < 0.05 vs. Aza group
P < 0.05 vs. Control group
Multiple regression analysis indicated S. was positively correlated with
Sute in both CsA (r = 0.4862, P < 0.001) and Aza (r = 0.5058, P < 0.047)
groups. Whereas a negative correlation existed between 5um and Cute or
Feurate in CsA group, and Sute and in Aza group. In conclusion, CsA
induced hyperuricemia seems to be related to lowered GFR.
Lipid abnormality in renal transplanted patients. Y.G. Kim, H.J.
Choi, S.H. Lee, SN. Yang, S.E. Park, and S.R. Lee, Department of
Internal Medicine, Kosin Medical College, Pusan, Korea. Among 249
renal transplanted cases performed by Kosin Medical College Kidney
Transplantation Team during 1984 through 1991, we studied 185 cases
(mean age; 35.4 year, M/F ratio; 2.3:1) for Ito 76 months after renal
transplantation. Thirty cases were treated with azathioprine (Aza) and
prednisolone (Pds) (Group A), 149 cases with cyclosporine (CsA) and
Pds (Group B) and 6 cases with CsA alone (Group C). The levels of
plasma total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycer-
ide and the LDL/HDL ratio were not significantly different between the
three groups. In 21.4% of Group A, 20.0% of Group B, and 66.6% of
Group C, the plasma cholesterol level was above 220 mg/dl. A total of
17.9% of Group A, 17.6% of Group B and 0% of Group C showed a
plasma triglyceride level of above 200 mg/dl. Until the 12th month
post-renal transplantation total cholesterol, LDL-cholesterol, HDL-
cholesterol, and triglyceride tended to be higher than pre-transplanta-
lion. However, the LDL/HDL ratio was generally lowered after trans-
plantation. Total cholesterol at 1 month after transplantation was higher
than before in both Group A (202.2 10.4 vs. 154.9 9.7 mg/dl, P <
0.05) and C (201.0 5.2 vs. 118.8 6.6 mg/dl, P < 0.05); the value at
12 months still remained high in Group C. HDL cholesterol was higher
at both 1st (54.8 2.7) and 12th (47.7 2.0) month as compared with
pre-transplantation level (38.4 2.6) (P < 0.05), whereas the LDL/
HDL ratio was lower at 1st (4.5 0.2), 3rd (4.8 0.3), 6th (4.6 0.2)
and 12th (4.3 0.2) months as compared with the pre-transplantation
level (5.4 0.2; P < 0.05) in Group C. Lipoprotein electrophoresis
demonstrated a normal pattern in all patients of both Group A (N = 13)
and C (N = 1), and type ha 8.8% and type IV 17.5% in Group B (N =
57). Multiple regression analysis of age, sex, body weight, daily CsA
and prednisolone dosage, CsA trough level, BUN, serum creatinine,
serum albumin, fasting blood sugar, fasting serum insulin level and total
cholesterol, HDL-cholesterol, triglyceride, and LDL/HDL ratio indi-
cated that BUN and serum creatinine correlated with LDL/HDL ratio(r = 0.2352, P < 0.05; r = 0.2290, P < 0.05 respectively) and serum
creatinine with total cholesterol (r = 0.1929, P = 0.035) in Group C.
Effect of human growth hormone (hGH) in growth retarded uremic
children. H.S. Han, 1'. Choi, H,R. Moon, and K. W. Ko, Department of
Pediatrics, College of Medicine, Seoul National University, Seoul,
Korea. Growth retardation has increased in clinical significance be-
cause of longer survival of uremic children from dialysis and transplan-
tation. Even with correction or minimization of many pathogenetic
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mechanisms in uremic growth retardation, catch up growth would not
occur. Recently, several investigators have reported successful growth
acceleration in these children. This study also attempted to examine the
growth accelerating effect of recently developed hGH in Korea. Growth
retarded prepubertal uremic children (height SDS <
—2.0; Bone age
C 11 years in girls, 11.5 years in boys) were given methionyl-hGH 0.125
mg/kg three times a week (0.75 U/kg/week) subcutaneously during the
evening for 6 months. Body measurements and routine laboratory tests
including serum Ca, P, albumin, cholesterol, thyroid function, CBC
were checked every 3 months. The causes of chronic renal failure were
congenital renal dysplasia in three and diffuse proliferative glomerulo-
nephritis in the other. Two were on hemodialysis, one on CAPD and
one on the conservative management. The age at hGH therapy was 11.8
2.3 years (8.4—14.7 years). The height SDS were —4.43 0.8 before
therapy and —4.42 0.9 at 6 months of therapy. The height velocity
rose from 2.97 0.74 to 6.02 1.87 cm/year. The difference of height
velocity between the patients and standard values rose from — 1.75
1.0 to +1.3 1.86 cm/year. The bone ages were 7.2 1.0 and 7.73
1.64 years before and after hUH therapy, respectively. The GH
antibody was not detected in all patients. Thus it appears that methio-
nyl-hGH promotes growth velocity in the growth retarded uremic
children, at least in short-term therapy.
Effect of immune complex (IC) on the proliferation and collagen
production in glomerular mesnnglal cells (MC). C.G, Ihm, J.K. Park,
J.H. Ahn, 1'. W. Lee, and M.J. Kim, Department of Internal Medicine,
Kyunghee University, School of Medicine, Seoul, Korea. MC produce
matrix components such as collagen, and it was reported that collagen
synthesis occurred very early in the anti-GBM and anti-Thyl antibody
glomerulonephritis models. Because IC binds to MC through Fc recep-
tor, we sought to determine whether IC could directly stimulate MC to
proliferate and produce collagen in vitro and whether these changes
could be modulated by therapeutic agents including heparmn, dexa-
methasone, indomethacin, enalapril and verapamil. Sixteen-hour expo-
sure to soluble IC (bovine gamma globulin and anti-bovine gamma
globulin antibody) reduced PH] thymidine uptake of MC by 36.5
4.0% (N = 5, P cc 0.05). The synthesis of collagen in cell layer by
subconfluent cultured MC was measured by [H] proline incorporation.
Collagenous and non-collagenous proteins were significantly increased
in response to IC, which were reduced by heparin (10 pg/mI; N = 6, P
<0.05). Also enalapril tended to reduce these increases in collagen by
29% (P cc 0.01), while other agents exerted no effects.
Non-
Group Collagenous collagenous
Normal 3.5 0.2 2.8 0.2
IC 5.1 o.5a 4.1 0.5k
Heparmn 3.8 0.4 3.4 0.5
Data are expressed as mean w; l0 cpm/1 x io cells.
a P C 0.05 vs. normal and heparin groups
These data indicate that IC directly affects the proliferation and
collagen production in MC, which may be pathogenic in the develop-
ment of mesangial expansion and/or sclerosis in vivo, and suggest that
heparin may retard this process, irrespective of anti-coagulation effect.
The effect of continuous urinary alkalinization on the prevention of
gentamicin nephrotoxlclty. H. I'. Lee, H.M. Bae, Y.K. Kim, K.H. Choi,
S.K. Ha, and D.S. Han, Department of Internal Medicine, Yonsei
University College of Medicine, Korea. The nephrotoxicity of amino-
glycoside antibiotics such as gentamicin, which is generally used in
severe infections including gram-negative bacterial infection, has been
a problem in clinical settings. To treat the infected patients with these
agents aggressively, a method to prevent nephrotoxicity is needed, The
study of continuous urinary alkalinization during gentamicia therapy in
Fisher 344 rats with regular renal function measurement and patholog-
ical examination suggested that it could reduce the nephrotoxicity of
gentamicin. To evaluate the preventive effects in humans, we studied
the effect of continuous urinary alknlinization on gentamicin nephro-
toxicity in patients who had normal renal function and in whom
gentamicin was indicated for their infections. We divided the patients
into three groups randomly. The first group was given gentamicin (3
mg/kg/day) only (control group), the second group given gentamicin (3
mg/kg/day) and sodium bicarbonate (6 g/day), and the third group given
gentamicin (3 mg/kg/day), sodium bicarbonate (6 g/day) and Diamox (1
g/day). Serum BUN and creatinine, creatinine clearance, urine pH,
urine ereatinine and urine beta-2-microglobulin (l32m) were measured
before, during, and after therapy. (1) A total of7l patients (13 males and
58 females) were studied. The mean age was 39.2 14.7 years in group
1, 36.8 14.7 in group 2, and 37.6 13.5 in group 3, which were not
significantly different. The infections of those 71 patients were acute
pyelonephritis in 48 cases, acute cystitis in 6 cases, pneumonia in 6
cases, gastroenteritis in 3 cases, salmonellosis in 2 cases, and others in
8 cases. (2) Significant urinary alkalinization was noted in groups 2 and
3 in which the increment of urinary pH other than baseline values on the
3rd, 7th and 14th days after gentamicin therapy were 1.00 1.08 (N =
4), 0.97 1.26 (N = 17) and 1.50 1.35 (N = 13) in group 2, and 1.20
2.20(N = 5),0.83 1.67 (N = 18) and 1.00 1.43 (N = 14)in group
3, compared with — 0.47 1.18 (N = 17), —0.10 1.17 (N = 24) and
0.00 1.13 (N = 10) in group 1. (3) The increase in serum creatinine
greater than 20 percent of baseline value was noted in 11.1% (3/27
patients) of group 1, 0.0% (0/20 patients) of group 2, and 21.1% (4/19
patients) of group 3 on the 7th day of therapy, and 20.0% (2/10 patients),
14.3% (2/14 patients) and 7.1% (1/14 patients) in each group on the 14th
day. (4) The creatinine clearances (ml/min/l .73 m2) before, on the 7th
and 14th days after therapy were 89.23 42.03, 97.11 37.60 and 97.69
33.49 in group 1, 100.04 39.23, 93.77 28.42 and 93.74 32.42 in
group 2, and 88.49 35.69, 88.61 34.39 and 88.58 29.74 in group 3.
There was no significant difference. (5) The baseline ratio of jJ2m/
creatinine in urine on the 3rd, 7th and 14th days after therapy were 1.67
2.83 (N = 7), 19.91 53.37 (N = 20) and 72.13 231.24 (N = 11) in
group 1, 1.44 2.24(N 4), 13.09 32.53 (N = 18) and 42.87 136.67(N = 13)in group 2, and 1.73 l.30(N= 5), 5.02 10.95 (N = 17) and
5.63 11.57 (N = 15) in group 3. The baseline ratio of 32m/creatinine
was decreased to 15.97 43.0 (N = 8), 4.58 7.89 (N = 9) and 1.93
3.56 (N = 5) in each group 3 days after the end of therapy. In
conclusion, urinary alkalinization showed the tendency of preventive
effects on gentamicin nephrotoxicity in humans, but follow-up studies
in the patients with high risks for the aminoglycoside nephrotoxicity
will be needed to define more definite preventive effects of urinary
alkalinization in these patients.
A case of relapsed minimal change nephrotic syndrome with multiple
hrnin infarction. J. Yoon, C. Y. Kim, H.P. Lim, and M.J. Kim,
Department of Internal Medicine, Inha University School of Medicine,
Incheon, Korea. Thromboembolic complications have long been rec-
ognized in nephrotic syndrome. The cause of thromboembolism is not
clear yet, but is likely related to hypercoagulability due to coagulation
factors and hyperaggregability of platelets. Also thromboembolism is
induced by the use of corticosteroid and diuretics, dehydration, trauma,
and venipuncture. The authors encountered a 24-year-old male patient
who had been admitted due to relapse of the nephrotic syndrome. The
patient complained of generalized edema, nausea and vomiting on initial
admission, with additionally severe headache and dysarthria. Com-
puted tomogram of brain showed infarction of left temporal lobe at that
time. He was treated with diuretics, steroid and anticoagulant. The
symptoms and signs of the nephrotic syndrome subsided without
neurologic manifestation. Eight months later, the patient showed severe
edema, ataxia, disorientation and weakness of right arm in addition to
above symptoms. Computed tomogram of the brain revealed more
progressed infarction on the left temporal lobe and recently developed
infarction on the cerebellar vermis. Obstruction of the posterotemporal
branch of the middle cerebral artery and the superior cerebellar artery
was suspected. Cerebral angiography was not performed because of
general condition. Percutaneous biopsy of the kidney revealed the
microscopic finding consistent with minimal change disease. The pa-
tient received phlebotomy, anticoagulant, and antiplatelet therapy. The
nephrotic syndrome was resolved, but ataxia and visual disturbance
remained as neurologic sequelae.
Comparison of differential renal function determination by mTe
DMSA and mTCDTPA. T.H. Kwon, S.H. Kim, D.K. Cho, J.T. Lee,
K.B. Lee, Department of Internal Medicine and Nuclear Medicine,
Kyungpook National University, School of Medicine, Taegu, Korea.
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Determination of split renal function is frequently important for diag-
nosis and follow-up of patients with renal disease. The classical
technique to perform split renal function studies requires cystoscopy
with bilateral ureteral catheterization. But this technique, associated
with patient discomfort and risk, may be inaccurate owing to contam-
ination of urine with blood or seepage of urine around the catheter.
Thus, a noninvasive means of determining individual renal function
would be advantageous in the surgical or medical management of renal
disease. mTechnetium DMSA is a scanning agent that provides a good
quality of renal image as a result of preferential cortical accumulation
and also makes feasible a quantitative assessment of separate kidney
function of each kidney. The relative renal uptake of mTechnetium
DMSA at 2, 4, and 24 hours postinjection was compared with the
relative glomerular filtration rate derived from using mTechnetium
DTPA in 58 patients. The results are as follows: (1) Relative mTech
netium DMSA uptake determined at 2, 4, and 24 hours postinjection
showed excellent correlation with the relative glomerular filtration rate
calculated from ssmTechnetium DTPA (r 0.9368, 0.9225, 0.9904,
respectively). (2) Although scans at 2 and 4 hours postinjection gave
satisfactory results, a 24-hour mTechnetium DMSA scan gave more
reliable data than scans at earlier time periods, since improved target-
to-background ratio due to decreased background activity was ob-
served at a 24-hour scan. In summary, there is a good correlation
between the relative renal uptake of mTechnetium DMSA at 2, 4, and
24 hours postinjection and that of ssmTechnetium DTPA at 2—3 minutes
postinjection. These data indicate that the relative renal uptake of
ssmTechnetjum DMSA is a reliable quantitative parameter for split renal
function.
A case of toxic shock syndrome in a patient with CAPD. S.H. Sohn,
H.S. Kim, Y.K. Kim, K.H. Choi, H. Y. Lee, D.S. Han, K.K. Lee, If.
Choi, and T.J. Jang, Department ofInternal Medicine and Department
ofPathology, Yonsei University College of Medicine, Seoul, Korea.
Toxic shock syndrome is an acute onset multisystem illness, and has a
clinical spectrum ranging from a relatively mild to a rapidly fatal illness.
The illness is associated with colonization or infection by strains of
Staphylococcus aureus, which produce toxic shock syndrome toxin 1.
We report a case of a toxic shock syndrome in a 68-year-old female
CAPD patient with the CAPD catheter cuff and tunnel infection. A
68-year-old end stage renal disease female patient on CAPD was
admitted to this hospital because of purulent discharge at the Tenckhoff
catheter insertion site for 45 days. Nine years ago she was diagnosed
with polycystic kidney disease. One year ago she started CAPD due to
ESRD. After the CAPD, two episodes of peritonitis were treated.
About 45 days prior to admission, localized swelling and yellowish
discharge were found at CAPD insertion site. Incision and drainage
were performed at the department of general surgery because of no
improvement with antibiotic therapy and pus culture revealed a growth
of Staphylococcus aureus. However, after I & D, purulent discharge
developed intermittently. She was admitted for removal of Tenckhoff
catheter under the impression of inner cuff and tunnel infection. On
admission there was no inflammatory signs such as redness, but a small
amount of purulent discharge was noted. 0.5 cm sized opening scar and
yellowish discharge were found. The Tenckhoff catheter was removed
under local anesthesia on the 4th hospital day, and operation findings
were frank abscess around both cuffs and subcutaneous tunnel. One
day after the removal, fever developed accompanied by shaking chills
and dizziness. She gradually became drowsy. Administration of antibi-
otics and dopamine was started. The blood cultures remained negative.
She also developed erythematous rashes at both antecubital areas
which spread to her whole body and which were darkened with crust,
and desquamation with serious discharge was started at the folding
area. On the 9th hospital day, her vital signs stabilized progressively,
her mental state became clear, and skin lesions almost disappeared on
the 19th hospital day. The patient was discharged with an improved
condition on the 50th hospital day.
Clinical outcome of Safe Lock system in CAPD. K. Y. Kim, S.H. Sohn,
H.S. Kim, Y.K. Kim, K,H. Choi, H. Y. Lee, and D.S. Han, Department
of Internal Medicine, College of Medicine, Yonsei University, Seoul,
Korea. We investigated the effect of Safe Lock connecting system of
CAPD in 34 ESRD patients from February, 1990, to February, 1991.
Seventeen patients started CAPD using Safe Lock system. Fifteen
patients changed their previous spike connector to Safe Lock system.
Two patients changed their dialysis modality from hemodialysis to
CAPD using Safe Lock system. The age distribution was 18—70 years
with the mean age of 42.4 13.0 years and the sex ratio was 13:21
(M:F). Seventeen patients who used Safe Lock system from the start of
CAPD experienced peritonitis with the incidence of 0.41/patient/year.
The incidence of peritonitis of 28 patients who had used Safe Lock
system more than 3 months were 0.80/patient/year. Patients who
changed connecting system from spike connector to Safe Lock system
showed that the incidence of peritonitis during the use of spike
connector were 1.74/patient/year. Eighteen out of 34 patients experi-
enced complications during the use of Safe Lock system. Peritonitis
was 18 times, abdominal pain noted in 11 patients, intraperitoneal
bleeding in 3 patients, exit site infection in 3 patients, adaptor discon-
nection in 2 patients, catheter obstruction in 1 patient and catheter
malposition in 1 patient. Blood chemistry and CBC improved in 17
patients who started CAPD with Safe Lock system. There were no
significant changes of laboratory values in 17 patients who received
other systems of dialysis before the use of Safe Lock system. In
conclusion, CAPD with Safe Lock connector system showed similar
dialysance compared with other conventional dialysate, lower tendency
in the episodes of peritonitis and was convenient in bag exchange
ompared to the conventional spike system.
Heterogeneous changes of plasma potassium levels in diabetic patients
with the acute hyperglycemia on oral glucose load. H. Y. Bae, S.D. Choi,
1. Park, C. 0. Moon, and H.J. Kim, Department of Internal Medicine,
College of Medicine, Chosun University, Kwangju, Korea. These
studies were performed in 10 chronic non-insulin-dependent diabetic
(NIDDM) and 4 control subjects to see whether diabetic ones are
following the well-known paradoxical increase in plasma potassium
after oral glucose load as insulin required diabetics or not, and to
determine the mechanism of changes of potassium levels if present. The
following data were observed: (1) Out of 10 diabetic subjects, after oral
glucose load, 6 patients (group 1) developed the paradoxical increase in
plasma potassium with maximal average change, 0.44 mEq/liter, at 120
mm (range, —0.8 to 2.07 mEq/liter). However, 4 diabetic patients
(group 2) as well as 4 control subjects showed uniform decrease in
plasma potassium with maximal average change, —0.36 and —0.34
mEq/liter (range, —0.02 to —0.5 and 0 to —0.57 mEq/liter) respectively.
(2) There was no significant difference between group 1 and group 2 in
baseline values of plasma aldosterone, creatinine, sodium and glucose,
but with significant difference in plasma potassium (3.592 0.29 vs.
4.008 0.19, P = 0.037),osmolality (288 6.1 vs. 300 4.1, P = 0.002)
and venous pH (7.422 0.028 vs. 7.365 0.023, P = 0.01), respec-
tively. (3) After oral glucose load, there was a similar slight elevation of
plasma glucose and osmolarity in group 2 and control, but with higher
response in group 1. Also, changes of plasma potassium were signifi-
cantly correlated with changes of plasma glucose and osmolarity though
no correlation with changes of venous pH. (4) There was no correlated
difference in changes of plasma sodium, aklosterone and plasma renin
activity on time course following the administration of oral glucose. In
conclusion, there was a heterogeneous response in changes of plasma
potassium levels in NIDDM with acute hyperglycemia following the
oral glucose load at least partly related to the hypertonicity and different
degree of insulin resistance in an individual subject.
Early electrophysiologic changes of peripheral neuropathy in renal
transplant recipients. G. Aeo, Y.S. Yoon, and B.K. Bang, Department
of Reh Med. Department of Internal Medicine, Catholic University
Medical College, Seoul, Korea. To evaluate changes in motor and
sensory nerve conduction parameters in renal transplant recipients, we
measured distal latency, amplitude, and conduction velocity of the
selected nerves (motor; median and peroneal n., sensory; median and
sural n.). Study was performed before (3.5 1.8 days) and after (1, 3
months) kidney transplantation. Mean age of 17 patients (M/F: 11/6)
was 40 (± 11) years. Prior to renal transplantation, 7 (35.3%) of 17
patients had evidence of subclinical neuropathy by electrodiagnostic
methods. Abnormal values were observed most frequently in amplitude
of sural sensory nerve (58.8%), distal latencies of sural sensory nerve
(41.2%), and distal latencies of median sensory nerve (29.4%). Early
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changes were observed in conduction velocity (56.7 5.7 mIs; P C
0.032) of median motor n. within 1 month after KT. Distal latencies of
median (3.1 0.2 msec; P C 0.029) and sural sensory (3.3 0.5 msec;
P C 0.048) nerve decreased significantly within 3 months after KT.
Through this study it was suggested that main parameters of subclinical
uremic neuropathy would be distal latency of sural sensory and median
motor n. and amplitude of sural sensory n. On the other hand, the most
sensitive indicator of regeneration after KT would be conduction
velocity of median nerve and distal latency of median and sural sensory
nerve.
The effect of HLA mismatching on living kidney graft survival in
Catholic Medical Center. Y.S. Yoon, B.K. Bang, WI. Kim, and Y.B.
Koh, Department of Internal Medicine, Department of Clinical Pathol-
ogy, Department of General Surgery, Catholic University Medical
College, Seoul, Korea. HLA matching continues to stand out as an
important factor in renal transplantation despite improvement in immu-
nosuppression. Therefore, we have analyzed 478 first living renal
transplants who had been treated with Aza (N = 68) or CsA (N = 410)
between April 1979 and March 1991 to determine the beneficial effect on
graft survival of HLA antigens matching. CsA significantly improved
kidney graft survival by 13% at 5 years as compared with Aza group
(77% vs. 64%; F> 0.05). Matching for the HLA-A + B significantly
improved kidney graft survival; the difference between the best (1
mismatches) and the poorest (2 mismatches) matched groups was 27%
at 5 years (67% vs. 40%; P C 0,05) in the Aza group, but not in the CsA
group. An impressive 34% difference in kidney graft survival was
observed at 5 years between the CsA-treated patients who received 0
and 2 HLA-DR mismatches (83% vs. 49%; P = 0.00001), but not
between Aza-treated patients. The 5-year kidney graft survival in the I
B + DR mismatched CsA group was 86%, which was significantly
different from 64% survival in the 4 B + DR mismatched group (P C
0.01), but not in the Aza group. The effect of HLA-A + DR and A + B
+ DR matching showed a little difference between the groups with
different mismatched numbers in the Aza and CsA groups. In conclu-
sion, matching for the HLA A + B significantly improved kidney graft
survival in the Aza group. Matching for the HLA-DR, B + DR
significantly improved kidney graft survival in the CsA group. The best
kidney graft survival was observed in the HLA-A + B + DR identical
combination treated with Aza (80% at 5 years), while in 0 HLA-A + B
mismatched recipients treated with CsA (95% at 5 years).
The influence of age on renal allograft survival. Y.S. Yoon, V.5. Kim,
LS. Park, S. V. Kim, W.S. Koo, Y.S. Chang, BK. Bang, and Y.B. Koh,
Division of Nephrology, Department of Internal Medicine, Department
of General Surgery, Catholic University Medical College, Seoul, Ko-
rea. Contradictory results have been reported concerning the outcome
of kidney transplantation in relation to donor and recipient age. We
have analyzed the Catholic Medical Center Transplant Registry data to
evaluate the effect of donor and recipient age on the outcome of renal
transplantation. Data from 578 first kidney transplants performed from
March, 1969 through March, 1991 were included in this analysis. The
tendency to use younger donors has gradually increased in the CsA era.
Donors under 30 years of age comprised 26% of the donors in Aza era
and rose to 37% in CsA era. There is an increased tendency to
transplant in patients older than 50. The number rose from 6% in Aza
era to 12% in CsA era. Graft survival rates ranged from 63—78% in the
Aza group as compared to the CsA group, 88—96% at 1 year for
recipient's age. Only the older recipients (over 51 years) had a low 63%
one year graft survival rate in the Aza group. Donor age had little effect
on graft survival. One-year graft survival rates were uniformly over
86% in transplants with 0, 1—2, 3—4 HLA-A + B and 0, 1 HLA-DR
antigen mismatched, regardless of donor and recipient age (except
when the donor was 31—40). However, one-year graft survival rates for
older donor and recipients (over 51 years) were 63% and 69%, respec-
tively when there were HLA-DR 2 mismatches. In conclusion, older
recipients (over 51 years) had a significantly lower one-year graft
survival rate in the Aza group. Also, graft survival rates for older
donors and recipients (over 51 years) were significantly lower when
there were 2 HLA-DR mismatches.
Factors influencing 2-year renal allograft survival. V.5. Yoon, S.A.
Yoon, S.f. An, f. V. Woo, and B.K. Bang, Department of Internal
Medicine, Catholic University Medical College, Seoul, Korea. The
improved 2-year renal transplant survival rate would lead one to predict
better long-term success rates, We have reviewed our recipients of
living and cadaveric donor transplants who retained their grafts for
greater than 2 years, focusing on the impact of pretransplantation
factors on late success. Several potential risk factors on late graft
survival were compared between 2-year survivor and non-survivor
groups; these variables included age, sex, donor source, diabetics,
HBV status, immunosuppressant, and HLA. A total 342 patients
underwent primary renal transplants (227 LRD, 106 NRD and 9 CAD)
from March, 1969 through March, 1989. A total of 266 (78%) of 342
primary renal transplants were still functioning at 2 years. Aza for
immunosuppression had significantly poorer 2-year graft survival (P =
0.00001). Age, sex, donor source, diabetics, HBV and HLA were not
significantly associated with poorer 2-year graft survival. In conclusion,
immunosuppressant was the single most important factor influencing
graft survival for more than 2 years.
Treatment of anemia of chronic renal failure with recomhlnant human
erythropoletla. V.5. Kim, J. V. Woo, I.S. Park, S. V. Kim, W.S. Koo,
V.5. Chang, V.5. Voon, and B.K. Bang, Department of Internal
Medicine, Catholic University Medical College, Seoul, Korea. To
examine the effects of erythropoietin on the anemia of chronic renal
disease and on the rate of renal deterioration, we administered recom-
binant human erythropoietin to 8 patients with anemia and progressive
renal failure who did not yet require dialysis (serum creatinine level, 1.9
to 8.2 mgldl) and to 24 anemic patients with end-stage renal disease who
were undergoing hemodialysis. The recombinant human erythropoietin
was given subcutaneously (starting dose 50 U/kg of body wt) twice a
week to predialysis patients and 14 hemodialyzed patients, and intra-
venously (starting dose 50 U/kg) three times a week to 10 hemodialyzed
patients for 12 weeks. The dose was reduced by one half when
hematocrit reached 30%. In predialysis patients, the mean hemoglobin
increased from 7.3 g/dl to 11.1 g/dl, mean hematoerit from 0.22 to 0.33,
mean RBC mass from 2.38 x l0'2/liter to 3.54 x l&2/liter, mean MCV
from 93.6 jt3 to 96.4 p? and mean plasma ferritin decreased from 329
ng/ml to 107 ng/ml, mean transferrin saturation ratio from 0.43 to 0.32.
We could not find any interval change of BUN and serum creatinine
during the erythropoietin treatment, In hemodialyzed patients with
intravenous injection, mean hemoglobin increased from 6.2 g/dl to 8.4
gIdI, mean hematoerit from 0.18 to 0.25, mean RBC mass from 1.93 x
l012/liter, to 2.78 x l0'2/liter, and transferrin saturation ratio decreased
from 0.34 to 0.24. In hemodialyzed patients with subcutaneous injec-
tion, mean hemoglobin increased from 6.1 g/dl to 11.7 g/dl, mean
hematocrit from 0.18 to 0.29, mean RBC mass from 2.02 x l0'2/liter, to
2.99 x l0'2/liter, and mean plasma ferritin decreased from 479 ng/ml to
179 ng/ml, mean transferrin saturation ratio from 0.52 to 0.36. During
erythropoietin treatment, none required transfusion, generalized pruri-
tus was present in one patient, headache was present in 7 patients and
hypertension worsened in 4 patients. In conclusion, erythropoietin
therapy is effective and safe in correcting the anemia of patients with
progressive renal failure and of hemodialyzed patients without affecting
renal function. Subcutaneous injection is as effective as intravenous
injection with relatively small doses.
Herpes simplex and Varleella zoster infection in renal transplant
recipIent. S.H. Park, J.D. Lee, B.U. Kim, S.f. An, V.S. Voon, andB.K.
Bang, Division of Nephrology, Department of Internal Medicine Cath-
olic University Medical College, Seoul, Korea. Five hundred and
twenty-five recipients of renal aliograft were studied for infection with
H. simplex and V. zoster after transplantation. To assess the incidence,
associated clinical features, and precipitating factors, we retrospec-
tively reviewed the records of patients undergoing renal transplantation
at Catholic Medical Center from May 1, 1984 through Jan 31, 1991.
Sixty-aloe (13.1%) of the 525 transplant recipients studied developed
herpetic mucocutaneous lesions. The incidence of infection in male and
female were 11.3% and 18.1%, respectively. In post-transplant diabet-
ics, the incidence of infection was higher than that of non-diabetics
(38.5%: 12.5%, P = 0.04 Fisher's exact test). Those who receive OK-T3
regimen had a higher incidence of infection than non-OK-T3 group
(56.3%: 11.8%, P = 0.001 Fisher's exact test). The primary sites of H.
simplex infection were perioral (67.6%), genital (29.4%), combined (3%)
and V.zoster were trigeminal (14.3%), cervical (11.4%), thoracic
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(42.8%), lumbar (2.9%), sacral (22.9%) and undefined (5.7%). Painful
eruption was developed from 38.8% by four weeks, 53.7% by eight
weeks, and 76,1% by twenty weeks. In conclusion: (1) The herpes
simplex and varicella zoster infection incidence is sixty-nine (13.1%).
(2) In post-transplant diabetes, the infection is greater than non-
diabetes. (3) Those who received OK-T3 because of graft rejection has
high incidence of herpertic infection. It is likely that diabetics and graft
rejection are potential risk factors in herpetic infection of renal trans-
plants.
Clinical experience with Swan Neck Tenckhoff catheters. Y.S. Kim,
S.J. Ahn, 1.5. Park, W.S. Koo, Y.S. Chang, Y.S. Yoon, andB.K. Bang,
Department of Internal Medicine, Catholic University Medical College,
Seoul, Korea. The Swan Neck Tenckhoff catheters are designed to
reduce major complications including peritonitis, exit site infection,
pericatheter leak and catheter tip migration. Between July 1989 and
December 1990, 80 Swan Neck Tenckhoff catheters were implanted in
Kangnam St. Mary's Hospital. We compared the clinical data from 80
Swan Neck Tenckhoff catheters and data from 35 standard Tenckhoff
catheters implanted between 1985 and 1989, retrospectively. In the
standard catheter group the mean age was 43 years, M:F ratio 25:10,
and diabetic patients were eight (23%). In the Swan Neck catheter
group, the mean age was 40 years, M:F ratio 21:29, and diabetic
patients were fifteen (30%). In the same period between July 1989 and
March 1991, the peritonitis rate and exit site infection rate in standard
catheter group were 1.15/12 patient months and 0.37/12 patient months,
and those in the Swan Neck catheter group were 0.70/12 patient months
(P < 0.05) and 0.11/12 patient months (P < 0.05), respectively. In
diabetic patients, the peritonitis rate of standard catheter and Swan
Neck catheter groups were 1.22/12 patient months and 1.01/12 patient
months (P > 0.05). In nondiabetic patients, however, the peritonitis
rate of standard catheter and Swan Neck catheter group were 1.14/12
patient months and 0.53/12 patient months (P < 0.05). In the Swan
Neck catheter group, pericatheter leak was present in only I case, and
catheter tip migration happened in 5 cases, of which 2 cases resulted in
catheter failure due to omental rapping. In conclusion, the Swan Neck
catheter is better than standard catheters to reduce the complication
rate.
Low volume peritoneal dialysis in newborns and young infants. S.H.
Ahn, Y.H. Park, and J.O. Hah, Department of Pediatrics, Yeungnam
University, School of Medicine, Taegu, Korea. Peritoneal dialysis (PD)
has been widely considered to be the dialytic treatment of choice for
acute renal failure (ARF) in infants and young children, because the
technique is simple, safe and easily adapted for these patients. Also, PD
in infants might have more effective ultrafiltration and clearance than in
adults. In certain circumstances associated with hemodynamic instabil-
ity, ordinary volume PD (30—50 mI/kg body weight per exchange) or
hemodialysis may not be suitable unfortunately. But frequently cycled,
low volume, high concentration PD may be more available to manage
the hemodynamically-unstable acute renal failure of newborns and
infants. Seven infants underwent PD due to volume overload (5) and
volume overload with hyperkalemia (2) with low exchange volume (14.2
4.2 mI/kg), short exchange time (30 to 45 minutes) and hypertonic
glucose solution (4.25% dextrose). Age was 1.9 1.3 months and body
weight was 4.6 1.6 kg. Etiology of ARF was secondary to sepsis with
or without shock (5) and postcardiac operation (2). PD catheter was
inserted percutaneously with pigtail catheter or Tenckhoff catheter. PD
solution was commercially obtained Peritosol® (Green Cross). Ultrafil-
tration per exchange was 124.6 13.4% versus 134.0 14.4% in
ordinary volume and concentration (1.5% dextrose) PD (4). In the two
infants with hyperkalemia, the potassium decreased from 8.7 mEq/liter
and 7.8 mEq/liter to 6.2 mEq/liter and 5.6 mEq/liter after six and five 30
minute exchanges of 10 to 15 mI/kg each. Serum BUN decreased from
95.7 37.5 to 75.7 25.9 mg/dl and blood pH increased from 7.122
0.048 to 7.326 0.063 after 24 hours of PD. We experienced two
episodes of hyperglycemia which were controlled by insulin and one of
mild hyponatremia during PD. In our experience, low volume and high
concentration PD with frequent exchange may have sufficient ultrafil-
tration and clearance without significant complications in the certain
risked ARF of infants.
Assessment of underweight patients with chronic renal failure on
hemodialysis. K.H. Sung, 1.H. Lee, M.C.H. Park, C.M. Kang, and
H.C. Park, Department of Internal Medicine, College of Medicine,
Han Yang University, Seoul Korea. Patients undergoing maintenance
hemodialysis often show evidence of wasting and malnutrition. We
observed 22 patients who were underweight (below 10% of ideal body
weight) in the Artificial Kidney Center of Han Yang University. We
assessed "adequacy of dialysis" and nutritional status of maintenance
hemodialysis patients for evaluating the cause of weight loss. The
results were as follows: (I) Of the 22 patients in this study, 6 cases were
female and 16 cases were male. Their ages ranged from 27 to 70 years.
(2) The rate of underweight state was 15.4%. (3) In 22 cases who were
underweight, there was one case of abnormal TACurea (over than 50
mg/dl) and one case of abnormal KT/V (lower than 1.2). (4) On GET
(gastric emptying time) study, 3 cases had abnormal delayed emptying
time. (5) Almost all patients did diet control, but in comparison with the
control group it was not significant. In conclusion, the results suggest
that the underweight patients are not influenced by suboptimal dialysis.
Thus, further study for nutritional status of maintenance hemodialysis
patients is needed.
